Human apoE Isoforms Differentially Regulate Brain Am

Science Translational Medicine

3, 89ra57

DOI: 10.1126/scitranslmed.3002156

Citation Report

#	Article	IF	Citations
1	Resolving controversies on the path to Alzheimer's therapeutics. Nature Medicine, 2011, 17, 1060-1065.	15.2	434
2	Amyloid Hypothesis and Alzheimer's Disease. , 2011, , .		3
3	GSK3 and Alzheimerâ€™s disease: facts and fictionâ€¦. Frontiers in Molecular Neuroscience, 2011, 4, 17.	1.4	128
4	New Data on Risk Gene for Alzheimer Disease Suggests Different Therapeutic Targets. Neurology Today: an Official Publication of the American Academy of Neurology, 2011, 11, 24-27.	0.0	1
5	The contribution of activated astrocytes to AÎ² production: Implications for Alzheimer's disease pathogenesis. Journal of Neuroinflammation, 2011, 8, 150.	3.1	278
6	Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders. Annals of Neurology, 2011, 70, 532-540.	2.8	536
7	Alzheimer's Disease and Non-Demented High Pathology Control Nonagenarians: Comparing and Contrasting the Biochemistry of Cognitively Successful Aging. PLoS ONE, 2011, 6, e27291.	1.1	65
8	Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-Î² Amyloidosis. Journal of Neuroscience, 2011, 31, 18007-18012.	1.7	166
9	Abca1 Deficiency Affects Alzheimer's Disease-Like Phenotype in Human ApoE4 But Not in ApoE3-Targeted Replacement Mice. Journal of Neuroscience, 2012, 32, 13125-13136.	1.7	105
10	Synapses and Alzheimer's Disease. Cold Spring Harbor Perspectives in Biology, 2012, 4, a005777-a005777.	2.3	340
11	Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006312-a006312.	2.9	637
12	Apolipoprotein E Promotes Î²-Amyloid Trafficking and Degradation by Modulating Microglial Cholesterol Levels. Journal of Biological Chemistry, 2012, 287, 2032-2044.	1.6	136
13	The neurobiology of Alzheimer disease defined by neuroimaging. Current Opinion in Neurology, 2012, 25, 1.	1.8	31
14	Upcoming candidate cerebrospinal fluid biomarkers of Alzheimerâ€™s disease. Biomarkers in Medicine, 2012, 6, 455-476.	0.6	100
15	Apolipoprotein E4 effects in Alzheimerâ€™s disease are mediated by synaptotoxic oligomeric amyloid-Î². Brain, 2012, 135, 2155-2168.	3.7	268
16	Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood AÎ² clearance in a mouse model of Î²-amyloidosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15502-15507.	3.3	138
17	Reducing Human Apolipoprotein E Levels Attenuates Age-Dependent AÎ² Accumulation in Mutant Human Amyloid Precursor Protein Transgenic Mice. Journal of Neuroscience, 2012, 32, 4803-4811.	1.7	143
18	Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of AÎ² amyloidosis. Journal of Experimental Medicine, 2012, 209, 2149-2156.	4.2	120

#	Article	IF	Citations
19	Differential Regulation of Amyloid-Î² Endocytic Trafficking and Lysosomal Degradation by Apolipoprotein E Isoforms. Journal of Biological Chemistry, 2012, 287, 44593-44601.	1.6	156
20	Brain Pericytes ABCA1 Expression Mediates Cholesterol Efflux but not Cellular Amyloid-Î² Peptide Accumulation. Journal of Alzheimer's Disease, 2012, 30, 489-503.	1.2	58
21	Investigators Identify Cytokine Target for APOE-Mediated Neurovascular Injury. Neurology Today: an Official Publication of the American Academy of Neurology, 2012, 12, 8-12.	0.0	0
22	Cerebral Î²-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE Îµ4 carriers. Aids, 2012, 26, 2327-2335.	1.0	95
23	Amyloid and Alzheimer's Disease: Inside and Out. Canadian Journal of Neurological Sciences, 2012, 39, 286-298.	0.3	56
24	Drug repositioning for Alzheimer's disease. Nature Reviews Drug Discovery, 2012, 11, 833-846.	21.5	239
25	The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update. Expert Opinion on Drug Discovery, 2012, 7, 281-297.	2.5	42
26	A breach in the bloodâ€“brain barrier. Nature, 2012, 485, 451-452.	13.7	25
27	Apolipoprotein E, amyloid-ÃŸ clearance and therapeutic opportunities in Alzheimer's disease. Alzheimer's Research and Therapy, 2012, 4, 32.	3.0	50
28	Genome-Environment Interactions That Modulate Aging: Powerful Targets for Drug Discovery. Pharmacological Reviews, 2012, 64, 88-101.	7.1	118
29	Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Human Molecular Genetics, 2012, 21, 4558-4571.	1.4	196
30	Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. DMM Disease Models and Mechanisms, 2012, 5, 746-55.	1.2	254
31	Neurovascular Defects and Faulty Amyloid-Î² Vascular Clearance in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S87-S100.	1.2	100
32	White matter hyperintensities predict amyloid increase in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 2766-2773.	1.5	115
33	Preventing Alzheimerâ€™s Disease. Science, 2012, 337, 1488-1492.	6.0	328
34	The CETP I405V polymorphism is associated with an increased risk of Alzheimerâ€™s disease. Aging Cell, 2012, 11, 228-233.	3.0	22
35	The toxic AÎ² oligomer and Alzheimer's disease: an emperor in need of clothes. Nature Neuroscience, 2012, 15, 349-357.	7.1	1,690
36	Small-Molecule Structure Correctors Target Abnormal Protein Structure and Function: Structure Corrector Rescue of Apolipoprotein E4â€“Associated Neuropathology. Journal of Medicinal Chemistry, 2012, 55, 8997-9008.	2.9	91

#	Article	IF	Citations
37	Role of ABC Transporters in the Pathogenesis of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2012, 3, 820-831.	1.7	107
38	Roles of Extracellular Chaperones in Amyloidosis. Journal of Molecular Biology, 2012, 421, 499-516.	2.0	55
39	Cholesterol enhances amyloid Î² deposition in mouse retina by modulating the activities of AÎ²-regulating enzymes in retinal pigment epithelial cells. Biochemical and Biophysical Research Communications, 2012, 424, 704-709.	1.0	20
40	Alzheimer Mechanisms and Therapeutic Strategies. Cell, 2012, 148, 1204-1222.	13.5	1,548
41	Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid Î² Peptide. Journal of Neuroscience, 2012, 32, 15181-15192.	1.7	219
42	Apolipoprotein C-I is an APOE genotype-dependent suppressor of glial activation. Journal of Neuroinflammation, 2012, 9, 192.	3.1	40
43	Apolipoprotein E, Not Fibrillar Î²-Amyloid, Reduces Cerebral Glucose Metabolism in Normal Aging. Journal of Neuroscience, 2012, 32, 18227-18233.	1.7	146
44	APOE4-specific Changes in AÎ² Accumulation in a New Transgenic Mouse Model of Alzheimer Disease. Journal of Biological Chemistry, 2012, 287, 41774-41786.	1.6	213
45	Tracking brain amyloid-Î² in presymptomatic Alzheimer's disease. Lancet Neurology, The, 2012, 11, 1018-1020.	4.9	3
46	Intraneuronal AÎ² accumulation and neurodegeneration: Lessons from transgenic models. Life Sciences, 2012, 91, 1148-1152.	2.0	81
47	Alzheimerâ€™s Disease Pathologic Cascades: Who Comes First, What Drives What. Neurotoxicity Research, 2012, 22, 182-194.	1.3	59
48	Apolipoprotein E Sets the Stage: Response to Injury Triggers Neuropathology. Neuron, 2012, 76, 871-885.	3.8	296
49	The Imbalance of Vascular Molecules in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 32, 699-709.	1.2	33
50	Multiple Î³-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimerâ€™s disease subjects. Molecular Neurodegeneration, 2012, 7, 16.	4.4	14
51	Measurement of apolipoprotein E and amyloid Î² clearance rates in the mouse brain using bolus stable isotope labeling. Molecular Neurodegeneration, 2012, 7, 14.	4.4	23
52	Multivariate Protein Signatures of Pre-Clinical Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Plasma Proteome Dataset. PLoS ONE, 2012, 7, e34341.	1.1	73
53	Galactic Cosmic Radiation Leads to Cognitive Impairment and Increased AÎ² Plaque Accumulation in a Mouse Model of Alzheimerâ€™s Disease. PLoS ONE, 2012, 7, e53275.	1.1	171
54	A Possible Role for CSF Turnover and Choroid Plexus in the Pathogenesis of Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 30, 17-26.	1.2	95

#	Article	IF	Citations
55	Apolipoprotein E: Essential Catalyst of the Alzheimer Amyloid Cascade. International Journal of Alzheimer's Disease, 2012, 2012, 1-9.	1.1	67
56	Silencing of Amyloid Precursor Protein Expression Using a New Engineered Delta Ribozyme. International Journal of Alzheimer's Disease, 2012, 2012, 1-12.	1.1	3
57	The Origins of Human Modernity. Humanities, 2012, 1, 1-53.	0.1	12
58	Historical perspectives on the discovery and development of drugs to treat neurological disorders. , 0, , 129-148.		5
59	Evidence for an effect of single nucleotide polymorphisms in SORL1 on cerebrospinal fluid markers of Alzheimerâ€™s disease. Future Neurology, 2012, 7, 123-126.	0.9	0
60	Low-density Lipoprotein Receptor Represents an Apolipoprotein E-independent Pathway of AÎ² Uptake and Degradation by Astrocytes. Journal of Biological Chemistry, 2012, 287, 13959-13971.	1.6	152
61	The Amyloid Beta Peptide: A Chemistâ€™s Perspective. Role in Alzheimerâ€™s and Fibrillization. Chemical Reviews, 2012, 112, 5147-5192.	23.0	785
62	AZ goes APOE. Science-Business EXchange, 2012, 5, 775-775.	0.0	0
63	The role of ECE1 variants in cognitive ability in old age and Alzheimer's disease risk. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 696-709.	1.1	11
64	Interaction between pathogenic proteins in neurodegenerative disorders. Journal of Cellular and Molecular Medicine, 2012, 16, 1166-1183.	1.6	104
65	Neuroscience-based Tests for Assessing Cognitive Changes in Normal Aging and in the Prodromal Phase of Alzheimerâ€™s Disease. Current Translational Geriatrics and Experimental Gerontology Reports, 2012, 1, 1-10.	0.7	0
66	Twenty years of Alzheimerâ€™s diseaseâ€causing mutations. Journal of Neurochemistry, 2012, 120, 3-8.	2.1	123
67	Alzheimer culprits: Cellular crossroads and interplay. Cellular Signalling, 2012, 24, 1831-1840.	1.7	76
68	Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice. Brain Research, 2012, 1467, 120-132.	1.1	31
69	APOE genotype alters glial activation and loss of synaptic markers in mice. Glia, 2012, 60, 559-569.	2.5	186
70	Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimerâ€™s disease and apoE TR mouse cortex. Acta Neuropathologica, 2012, 123, 39-52.	3.9	48
71	Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Molecular Neurodegeneration, 2013, 8, 18.	4.4	75
72	ApoE4 induces AÎ²42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice. Molecular Neurodegeneration, 2013, 8, 16.	4.4	93

#	Article	IF	Citations
73	In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Molecular Neurodegeneration, 2013, 8, 13.	4.4	103
74	Integrative genomics identifies APOE Îµ4 effectors in Alzheimer's disease. Nature, 2013, 500, 45-50.	13.7	148
75	Ushering in the study and treatment of preclinical Alzheimer disease. Nature Reviews Neurology, 2013, 9, 371-381.	4.9	125
76	Genetic Susceptibility for Alzheimer Disease Neuritic Plaque Pathology. JAMA Neurology, 2013, 70, 1150.	4.5	143
77	Role of the cannabinoid system in the transit of beta-amyloid across the bloodâ€“brain barrier. Molecular and Cellular Neurosciences, 2013, 56, 255-262.	1.0	39
78	Molecular links between Alzheimerâ€™s disease and diabetes mellitus. Neuroscience, 2013, 250, 140-150.	1.1	173
79	Effect of Apolipoprotein E Genotype and Diet on Apolipoprotein E Lipidation and Amyloid Peptides. JAMA Neurology, 2013, 70, 972.	4.5	85
80	Regulation of prostaglandin F2Î± against Î² amyloid clearance and its inflammation induction through LXR/RXR heterodimer antagonism in microglia. Prostaglandins and Other Lipid Mediators, 2013, 106, 45-52.	1.0	21
81	Gene Transfer of Human Apoe Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain. Science Translational Medicine, 2013, 5, 212ra161.	5.8	135
82	Biology and Genetics of Prions Causing Neurodegeneration. Annual Review of Genetics, 2013, 47, 601-623.	3.2	384
83	Models of Alzheimerâ€™s Disease. , 2013, , 595-632.		0
84	Biomarker Modeling of Alzheimerâ€™s Disease. Neuron, 2013, 80, 1347-1358.	3.8	773
85	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurology, The, 2013, 12, 957-965.	4.9	471
86	Apolipoprotein Ε Îµ4 Frequency Is Increased among Chinese Patients with Frontotemporal Dementia and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2013, 36, 163-170.	0.7	25
87	Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker. Alzheimer's Research and Therapy, 2013, 5, 8.	3.0	113
88	Evidence for impaired amyloid Î² clearance in Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 33.	3.0	172
89	Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology, 2013, 9, 106-118.	4.9	2,482
90	APOE Ïµ4 Increases Risk for Dementia in Pure Synucleinopathies. JAMA Neurology, 2013, 70, 223.	4.5	302

#	Article	IF	Citations
91	Cerebrovascular Effects of Apolipoprotein E. JAMA Neurology, 2013, 70, 440.	4.5	218
92	Stimulation of the Retinoid X Receptor Facilitates Beta-Amyloid Clearance Across the Bloodâ€“Brain Barrier. Journal of Molecular Neuroscience, 2013, 49, 270-276.	1.1	38
93	Blocking the Interaction between Apolipoprotein E and AÎ² Reduces Intraneuronal Accumulation of AÎ² and Inhibits Synaptic Degeneration. American Journal of Pathology, 2013, 182, 1750-1768.	1.9	70
94	APOE3, but Not APOE4, Bone Marrow Transplantation Mitigates Behavioral and Pathological Changes in a Mouse Model of Alzheimer Disease. American Journal of Pathology, 2013, 183, 905-917.	1.9	28
95	Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth. NeuroImage, 2013, 78, 474-480.	2.1	40
96	Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. Nature Reviews Neuroscience, 2013, 14, 293-304.	4.9	106
97	The Pro-Neurotrophin Receptor Sortilin Is a Major Neuronal Apolipoprotein E Receptor for Catabolism of Amyloid-Î² Peptide in the Brain. Journal of Neuroscience, 2013, 33, 358-370.	1.7	86
98	Metallostasis in Alzheimer's disease. Free Radical Biology and Medicine, 2013, 62, 76-89.	1.3	297
99	Toward the Treatment and Prevention of Alzheimer's Disease: Rational Strategies and Recent Progress. Annual Review of Medicine, 2013, 64, 367-383.	5.0	89
100	Extracellular Chaperones and Proteostasis. Annual Review of Biochemistry, 2013, 82, 295-322.	5.0	156
101	Levels of Soluble Apolipoprotein E/Amyloid-Î² (AÎ²) Complex Are Reduced and Oligomeric AÎ² Increased with APOE4 and Alzheimer Disease in a Transgenic Mouse Model and Human Samples*. Journal of Biological Chemistry, 2013, 288, 5914-5926.	1.6	136
102	The missing link in the amyloid cascade of Alzheimerâ€™s disease â€“ Metal ions. Neurochemistry International, 2013, 62, 367-378.	1.9	72
103	GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimerâ€™s Disease. Neuron, 2013, 78, 256-268.	3.8	344
104	Widening Spectrum of Prions Causing Neurodegenerative Diseases. Research and Perspectives in Alzheimer's Disease, 2013, , 1-17.	0.1	1
106	Amelioration of cognitive deficits in plaqueâ€bearing <scp>A</scp>lzheimer's disease model mice through selective reduction of nascent soluble A42 without affecting other A pools. Journal of Neurochemistry, 2013, 125, 465-472.	2.1	15
107	Brain interstitial oligomeric amyloid Î² increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. FASEB Journal, 2013, 27, 3239-3248.	0.2	57
108	Epigenetic mechanisms in Alzheimer's disease: Implications for pathogenesis and therapy. Ageing Research Reviews, 2013, 12, 1024-1041.	5.0	110
109	Binding of Apolipoprotein E Inhibits the Oligomer Growth of Amyloid-Î² Peptide in Solution as Determined by Fluorescence Cross-correlation Spectroscopy. Journal of Biological Chemistry, 2013, 288, 11628-11635.	1.6	39

#	Article	IF	Citations
110	Cognitive Impairment in Neurological Diseases: Lessons from Apolipoprotein E. Journal of Alzheimer's Disease, 2013, 38, 1-9.	1.2	16
111	In Vivo and In Vitro Effects of an Apolipoprotein E Mimetic Peptide on Amyloid-Î² Pathology. Journal of Alzheimer's Disease, 2013, 36, 335-347.	1.2	42
112	Concerning the structure of apoE. Protein Science, 2013, 22, 1820-1825.	3.1	28
113	Modification of the Relationship of the Apolipoprotein E Îµ4 Allele to the Risk of Alzheimer Disease and Neurofibrillary Tangle Density by Sleep. JAMA Neurology, 2013, 70, 1544.	4.5	216
114	APOE Îµ4, Alzheimerâ€™s disease pathology, cerebrovascular disease, and cognitive change over the years prior to death.. Psychology and Aging, 2013, 28, 1015-1023.	1.4	41
115	New Genes and New Insights from Old Genes. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 358-371.	0.4	15
116	ApoE influences amyloid-Î² (AÎ²) clearance despite minimal apoE/AÎ² association in physiological conditions. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1807-16.	3.3	428
117	Apolipoprotein E gene, environmental risk factors, and their interactions in dementia among seniors. International Journal of Geriatric Psychiatry, 2013, 28, 1005-1014.	1.3	29
118	Deletion ofAbca7Increases Cerebral Amyloid-Î² Accumulation in the J20 Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2013, 33, 4387-4394.	1.7	165
119	The ABCA7 transporter, brain lipids and Alzheimerâ€™s disease. Clinical Lipidology, 2013, 8, 97-108.	0.4	1
120	APOE-Dependent Phenotypes in Subjects with Mild Cognitive Impairment Converting to Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 37, 389-401.	1.2	13
121	Effect of Kidney Dysfunction on Cortical Thinning in Patients with Probable Alzheimer's Disease Dementia. Journal of Alzheimer's Disease, 2013, 33, 961-968.	1.2	11
122	The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Frontiers in Aging Neuroscience, 2013, 5, 11.	1.7	126
123	Î²-Amyloid oligomers in aging and Alzheimerâ€™s disease. Frontiers in Aging Neuroscience, 2013, 5, 28.	1.7	54
124	Metal Dyshomeostasis and Inflammation in Alzheimerâ€™s and Parkinsonâ€™s Diseases: Possible Impact of Environmental Exposures. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-19.	1.9	99
125	Metals and cholesterol: two sides of the same coin in AlzheimerÃ¢â‚¬â„¢s disease pathology. Frontiers in Aging Neuroscience, 2014, 6, 91.	1.7	36
126	Interactions of metals and Apolipoprotein E in AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Aging Neuroscience, 2014, 6, 121.	1.7	46
127	Aging reduces glial uptake and promotes extracellular accumulation of AÃŽÂ² from a lentiviral vector. Frontiers in Aging Neuroscience, 2014, 6, 210.	1.7	22

#	Article	IF	Citations
128	Haptoglobin increases with age in rat hippocampus and modulates Apolipoprotein E mediated cholesterol trafficking in neuroblastoma cell lines. Frontiers in Cellular Neuroscience, 2014, 8, 212.	1.8	23
129	Contributions and complexities from the use of in vivo animal models to improve understanding of human neuroimaging signals. Frontiers in Neuroscience, 2014, 8, 211.	1.4	37
130	Blood Genome-Wide Transcriptional Profiles Reflect Broad Molecular Impairments and Strong Blood-Brain Links in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 93-108.	1.2	48
131	Apolipoprotein E Isoform-Specific Effects on Lipoprotein Receptor Processing. NeuroMolecular Medicine, 2014, 16, 686-696.	1.8	41
132	Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease. Acta Neuropathologica Communications, 2014, 2, 135.	2.4	246
133	Lipidomics of Alzheimerâ€™s disease. Bioanalysis, 2014, 6, 541-561.	0.6	43
134	Apolipoprotein E in Synaptic Plasticity and Alzheimerâ€™s Disease: Potential Cellular and Molecular Mechanisms. Molecules and Cells, 2014, 37, 767-776.	1.0	113
135	Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 266-273.	0.9	47
136	Potential Therapeutic Strategies for Alzheimerâ€™s Disease Targeting or BeyondÎ²-Amyloid: Insights from Clinical Trials. BioMed Research International, 2014, 2014, 1-22.	0.9	61
137	APOE and BDNF Val66Met polymorphisms combine to influence episodic memory function in older adults. Behavioural Brain Research, 2014, 271, 309-315.	1.2	50
138	Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders. PLoS Computational Biology, 2014, 10, e1003956.	1.5	151
139	Unlocking truths of Î³-secretase in Alzheimer's disease: what is the translational potential?. Future Neurology, 2014, 9, 419-429.	0.9	12
140	ECM receptors in neuronal structure, synaptic plasticity, and behavior. Progress in Brain Research, 2014, 214, 101-131.	0.9	72
141	Blocking the apolipoprotein E/Amyloid Î² interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid Î² and tau pathology. Journal of Neurochemistry, 2014, 128, 577-591.	2.1	50
142	Cognitive decline and brain pathology in aging â€“ need for a dimensional, lifespan and systems vulnerability view. Scandinavian Journal of Psychology, 2014, 55, 244-254.	0.8	42
143	Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis. Journal of Neurochemistry, 2014, 129, 559-572.	2.1	155
144	An updated Alzheimerâ€™s disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 581-598.	0.8	29
145	Autophagy in microglia degrades extracellular Î²-amyloid fibrils and regulates the NLRP3 inflammasome. Autophagy, 2014, 10, 1761-1775.	4.3	322

#	Article	IF	Citations
146	Altered CpG methylation in sporadic Alzheimer's disease is associated with APP and MAPT dysregulation. Human Molecular Genetics, 2014, 23, 648-656.	1.4	126
147	Lysosomal Sorting of Amyloid-Î² by the SORLA Receptor Is Impaired by a Familial Alzheimerâ€™s Disease Mutation. Science Translational Medicine, 2014, 6, 223ra20.	5.8	131
148	Role of cholesterol metabolism in the pathogenesis of AlzheimerÊ¼s disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2014, 17, 319-323.	1.3	38
149	Apolipoprotein E increases cell association of amyloid-Î² 40 through heparan sulfate and LRP1 dependent pathways. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 76-87.	1.4	12
150	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, 2014, 71, 1183.	6.0	85
151	Buying time: a rationale for examining the use of circadian rhythm and sleep interventions to delay progression of mild cognitive impairment to AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Aging Neuroscience, 2014, 6, 325.	1.7	72
152	Clinical Predictors of Severe Cerebral Amyloid Angiopathy and Influence ofAPOEGenotype in Persons With Pathologically Verified Alzheimer Disease. JAMA Neurology, 2014, 71, 878.	4.5	50
153	Is Apolipoprotein E Required for Cognitive Function in Humans?. JAMA Neurology, 2014, 71, 1213.	4.5	8
154	APOE-epsilon4 and aging of medial temporal lobe gray matter in healthy adults older than 50 years. Neurobiology of Aging, 2014, 35, 2479-2485.	1.5	36
155	CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathologica, 2014, 127, 621-632.	3.9	60
156	Apolipoprotein E, gender, and Alzheimerâ€™s disease: an overlooked, but potent and promising interaction. Brain Imaging and Behavior, 2014, 8, 262-273.	1.1	165
157	The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Research Bulletin, 2014, 103, 18-28.	1.4	89
158	High-Density Lipoproteins and Cerebrovascular Integrity in Alzheimerâ€™s Disease. Cell Metabolism, 2014, 19, 574-591.	7.2	76
159	Soluble apoE/AÎ² complex: mechanism and therapeutic target for APOE4-induced AD risk. Molecular Neurodegeneration, 2014, 9, 2.	4.4	98
160	ApoE and AÎ² in Alzheimerâ€™s Disease: Accidental Encounters or Partners?. Neuron, 2014, 81, 740-754.	3.8	460
161	Apolipoprotein E in Alzheimer's Disease: An Update. Annual Review of Neuroscience, 2014, 37, 79-100.	5.0	340
162	What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Progress in Neurobiology, 2014, 117, 20-40.	2.8	608
163	Genetic markers for diagnosis and pathogenesis of Alzheimer's disease. Gene, 2014, 545, 185-193.	1.0	109

#	Article	IF	Citations
164	Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimerâ€™s disease patients and controls. Acta Neuropathologica, 2014, 127, 633-643.	3.9	120
165	Understanding the cause of sporadic Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2014, 14, 621-630.	1.4	47
166	Common defects of mitochondria and iron in neurodegeneration and diabetes (MIND): A paradigm worth exploring. Biochemical Pharmacology, 2014, 88, 573-583.	2.0	13
167	Human APOE genotype affects intraneuronal AÂ1-42 accumulation in a lentiviral gene transfer model. Human Molecular Genetics, 2014, 23, 1365-1375.	1.4	35
168	Amyloid-Î² Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in Vivo. Journal of Biological Chemistry, 2014, 289, 30538-30555.	1.6	82
169	Does metabolic failure at the synapse cause Alzheimerâ€™s disease?. Medical Hypotheses, 2014, 83, 802-808.	0.8	10
170	LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice. Journal of Lipid Research, 2014, 55, 1721-1729.	2.0	5
171	Anti-ApoE Antibody Given after Plaque Onset Decreases AÎ² Accumulation and Improves Brain Function in a Mouse Model of AÎ² Amyloidosis. Journal of Neuroscience, 2014, 34, 7281-7292.	1.7	102
172	Molecular Mechanisms of Alzheimer Disease Protection by the A673T Allele of Amyloid Precursor Protein. Journal of Biological Chemistry, 2014, 289, 30990-31000.	1.6	153
173	More than Cholesterol Transporters: Lipoprotein Receptors in CNS Function and Neurodegeneration. Neuron, 2014, 83, 771-787.	3.8	127
174	Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiology of Disease, 2014, 72, 3-12.	2.1	500
175	Functional and Structural MRI in Alzheimerâ€™s Disease: A Multimodal Approach. , 2014, , 371-422.		0
176	APOE2 enhances neuroprotection against Alzheimerâ€™s disease through multiple molecular mechanisms. Molecular Psychiatry, 2014, 19, 1243-1250.	4.1	156
177	HDL and cognition in neurodegenerative disorders. Neurobiology of Disease, 2014, 72, 22-36.	2.1	118
178	Human APOE4 increases microglia reactivity at AÎ² plaques in a mouse model of AÎ² deposition. Journal of Neuroinflammation, 2014, 11, 111.	3.1	144
179	Blocking the apoE/AÎ² interaction ameliorates AÎ²-related pathology in APOE Îµ2 and Îµ4 targeted replacement Alzheimer model mice. Acta Neuropathologica Communications, 2014, 2, 75.	2.4	42
180	Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Reports, 2014, 15, 1036-1052.	2.0	224
181	Lipoprotein-Based Nanoparticles Rescue the Memory Loss of Mice with Alzheimerâ€™s Disease by Accelerating the Clearance of Amyloid-Beta. ACS Nano, 2014, 8, 2345-2359.	7.3	179

#	Article	IF	Citations
182	Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. Neurobiology of Aging, 2014, 35, 819-826.	1.5	67
183	Pathways to Alzheimer's disease. Journal of Internal Medicine, 2014, 275, 296-303.	2.7	159
184	Association of plasma and cortical amyloid beta is modulated by APOE Îµ4 status. Alzheimer's and Dementia, 2014, 10, e9-e18.	0.4	43
185	Alzheimerâ€™s Disease Genetics: From the Bench to the Clinic. Neuron, 2014, 83, 11-26.	3.8	396
186	Insulin Reverses the High-Fat Dietâ€“Induced Increase in Brain AÎ² and Improves Memory in an Animal Model of Alzheimer Disease. Diabetes, 2014, 63, 4291-4301.	0.3	197
187	Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimerâ€™s disease. Neuroscience Bulletin, 2014, 30, 317-330.	1.5	77
188	New Targets for the Development of PET Tracers for Imaging Neurodegeneration in Alzheimer Disease. Journal of Nuclear Medicine, 2014, 55, 1221-1224.	2.8	26
189	LRP-1 polymorphism is associated with global and regional amyloid load in Alzheimer's disease in humans in-vivo. NeuroImage: Clinical, 2014, 4, 411-416.	1.4	15
190	Phosphorylated Tau-AÎ²42 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimerâ€™s Disease in Multiplex Immunoassay Panels of Cerebrospinal Fluid. Biological Psychiatry, 2014, 75, 723-731.	0.7	72
191	Association of cerebrospinal fluid AÎ²42 with A2M gene in cognitively normal subjects. Neurobiology of Aging, 2014, 35, 357-364.	1.5	6
192	Neuronal activity regulates extracellular tau in vivo. Journal of Experimental Medicine, 2014, 211, 387-393.	4.2	429
193	HDL and cholesterol handling in the brain. Cardiovascular Research, 2014, 103, 405-413.	1.8	172
194	Functions of the CB1 and CB2 Receptors in Neuroprotection at the Level of the Bloodâ€“Brain Barrier. NeuroMolecular Medicine, 2014, 16, 620-642.	1.8	50
195	APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Molecular Psychiatry, 2014, 19, 351-357.	4.1	181
196	Botanics: a potential source of new therapies for Alzheimer's disease?. Botanics: Targets and Therapy, 0, , 11.	0.3	5
197	White Matter Hyperintensities are associated with Amyloid Burden in APOE4 Non-Carriers. Journal of Alzheimer's Disease, 2014, 40, 877-886.	1.2	34
198	Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathologica Communications, 2015, 3, 70.	2.4	45
199	Potential Therapeutic Implications of Gelsolin in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 13-25.	1.2	12

#	Article	IF	Citations
200	Amyloid-Î² and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2015, 46, 261-269.	1.2	39
201	Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years. Journal of Alzheimer's Disease, 2015, 49, 733-741.	1.2	18
202	Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimerâ€™s Disease Prevention and Early Intervention. Journal of Alzheimer's Disease, 2015, 48, 411-424.	1.2	76
203	Reduced phosphorylation of brain insulin receptor substrate and Akt proteins in apolipoprotein-E4 targeted replacement mice. Scientific Reports, 2015, 4, 3754.	1.6	37
204	Analysis of in vivo turnover of tau in a mouse model of tauopathy. Molecular Neurodegeneration, 2015, 10, 55.	4.4	60
205	Impaired vascular-mediated clearance of brain amyloid beta in Alzheimerâ€™s disease: the role, regulation and restoration of LRP1. Frontiers in Aging Neuroscience, 2015, 7, 136.	1.7	160
206	The past and the future of Alzheimer's disease CSF biomarkersâ€”a journey toward validated biochemical tests covering the whole spectrum of molecular events. Frontiers in Neuroscience, 2015, 9, 345.	1.4	66
207	Modeling the Role of the Glymphatic Pathway and Cerebral Blood Vessel Properties in Alzheimerâ€™s Disease Pathogenesis. PLoS ONE, 2015, 10, e0139574.	1.1	67
208	Therapeutic Actions of the Thiazolidinediones in Alzheimerâ€™s Disease. PPAR Research, 2015, 2015, 1-8.	1.1	49
210	Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer's Disease. Current Alzheimer Research, 2015, 13, 7-17.	0.7	40
211	Stem cell therapy for Alzheimerâ€™s disease and related disorders: current status and future perspectives. Experimental and Molecular Medicine, 2015, 47, e151-e151.	3.2	62
212	What does it mean to be â€˜amyloid-positiveâ€™?. Brain, 2015, 138, 514-516.	3.7	17
213	Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and AÎ² metabolism in apoE4-targeted replacement mice. Molecular Neurodegeneration, 2015, 10, 6.	4.4	114
214	Alzheimer Disease. , 2015, , 753-768.		6
215	Apolipoprotein E gene polymorphism and Alzheimer's disease in Chinese population: a meta-analysis. Scientific Reports, 2014, 4, 4383.	1.6	61
216	Assessing Cognitive Improvement in People with Down Syndrome: Important Considerations for Drug-Efficacy Trials. Handbook of Experimental Pharmacology, 2015, 228, 335-380.	0.9	8
217	Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nature Neuroscience, 2015, 18, 800-806.	7.1	582
218	Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2015, 74, 672-687.	0.9	33

#	Article	IF	Citations
219	ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease. Future Medicinal Chemistry, 2015, 7, 2451-2467.	1.1	82
220	Effects of growth hormoneâ€“releasing hormone on sleep and brain interstitial fluid amyloid-Î² in an APP transgenic mouse model. Brain, Behavior, and Immunity, 2015, 47, 163-171.	2.0	12
221	The benefit of docosahexaenoic acid for the adult brain in aging and dementia. Prostaglandins Leukotrienes and Essential Fatty Acids, 2015, 92, 15-22.	1.0	69
222	<scp>APOE</scp>Îµ2 is associated with milder clinical and pathological <scp>A</scp>lzheimer disease. Annals of Neurology, 2015, 77, 917-929.	2.8	132
223	Different mechanisms of apolipoprotein E isoformâ€dependent modulation of prostaglandin E ₂ production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia. FASEB Journal, 2015, 29, 1754-1762.	0.2	44
224	Localization and Trafficking of Amyloid-Î² Protein Precursor and Secretases: Impact on Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 329-347.	1.2	64
225	The epigenetics of aging and neurodegeneration. Progress in Neurobiology, 2015, 131, 21-64.	2.8	334
226	Stabilization of intracellular trafficking and metabolism of amyloid Î²â€protein precursor and Alcadein Î² by apolipoprotein E. FEBS Letters, 2015, 589, 2394-2400.	1.3	3
227	Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurology, 2015, 72, 1029.	4.5	237
228	Zinc affects the proteolytic stability of Apolipoprotein E in an isoform-dependent way. Neurobiology of Disease, 2015, 81, 38-48.	2.1	16
229	Analyzing dendritic spine pathology in Alzheimerâ€™s disease: problems and opportunities. Acta Neuropathologica, 2015, 130, 1-19.	3.9	154
230	Lipids in Amyloid-Î² Processing, Aggregation, and Toxicity. Advances in Experimental Medicine and Biology, 2015, 855, 67-94.	0.8	56
231	Dementia of the eye: the role of amyloid beta in retinal degeneration. Eye, 2015, 29, 1013-1026.	1.1	133
232	Apolipoprotein E Inhibits Cerebrovascular Pericyte Mobility through a RhoA Protein-mediated Pathway. Journal of Biological Chemistry, 2015, 290, 14208-14217.	1.6	49
233	Map kinase and PKC signaling pathways modulate NGF-mediated apoE transcription. Neuroscience Letters, 2015, 595, 54-59.	1.0	8
234	Genetic Variants and Related Biomarkers in Sporadic Alzheimerâ€™s Disease. Current Genetic Medicine Reports, 2015, 3, 19-25.	1.9	3
235	Cerebrospinal Fluid Biomarkers of Neurovascular Dysfunction in Mild Dementia and Alzheimer'S Disease. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1055-1068.	2.4	92
236	Candidate Genes That Affect Aging Through Protein Homeostasis. Advances in Experimental Medicine and Biology, 2015, 847, 45-72.	0.8	7

#	Article	IF	Citations
237	Alzheimer's Disease: Behavioral and Social Aspects. , 2015, , 584-590.		1
238	Molecular mechanisms linking amyloid Î² toxicity and Tau hyperphosphorylation in Alzheimer×³s disease. Free Radical Biology and Medicine, 2015, 83, 186-191.	1.3	101
239	Do glia drive synaptic and cognitive impairment in disease?. Nature Neuroscience, 2015, 18, 1539-1545.	7.1	344
240	Interaction of ApoE3 and ApoE4 isoforms with an ITM2b/BRI2 mutation linked to the Alzheimer disease-like Danish dementia: Effects on learning and memory. Neurobiology of Learning and Memory, 2015, 126, 18-30.	1.0	12
241	Immunohistochemical analysis of transporters related to clearance of amyloid-Î² peptides through bloodâ€“cerebrospinal fluid barrier in human brain. Histochemistry and Cell Biology, 2015, 144, 597-611.	0.8	37
242	GM1-Modified Lipoprotein-like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimerâ€™s Disease. ACS Nano, 2015, 9, 10801-10816.	7.3	94
243	Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor Î³ Agonist Treatment Reduces Amyloid Î² Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. Journal of Biological Chemistry, 2015, 290, 21591-21602.	1.6	71
244	Alzheimer's disease: rare variants with large effect sizes. Current Opinion in Genetics and Development, 2015, 33, 49-55.	1.5	33
245	Role of Syndecans in Lipid Metabolism and Human Diseases. Advances in Experimental Medicine and Biology, 2015, 855, 241-258.	0.8	14
246	Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimerâ€™s disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11965-11970.	3.3	111
247	The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin. Neurobiology of Disease, 2015, 81, 49-65.	2.1	115
248	APOE and cerebral amyloid angiopathy in community-dwelling older persons. Neurobiology of Aging, 2015, 36, 2946-2953.	1.5	76
249	Alzheimerâ€™s Disease Risk Genes and Mechanisms of Disease Pathogenesis. Biological Psychiatry, 2015, 77, 43-51.	0.7	1,034
250	Risk Factors for Alzheimerâ€™s Disease. , 2016, , .		1
251	Apolipoprotein E4: A Risk Factor for Successful Cognitive Aging. Dementia and Neurocognitive Disorders, 2016, 15, 61.	0.4	1
252	The Aging Mind in Transition. , 2016, , 87-103.		3
253	Emerging Link between Alzheimerâ€™s Disease and Homeostatic Synaptic Plasticity. Neural Plasticity, 2016, 2016, 1-19.	1.0	67
254	Alzheimerâ€™s-Related Amyloid Beta Peptide Aggregates in the Ageing Retina: Implications for Sight Loss and Dementia. , 0, , .		2

#	Article	IF	Citations
255	Genes associated with Alzheimer's disease: an overview and current status. Clinical Interventions in Aging, 2016, 11, 665.	1.3	235
256	Concurrence of High Fat Diet and APOE Gene Induces Allele Specific Metabolic and Mental Stress Changes in a Mouse Model of Alzheimerâ€™s Disease. Frontiers in Behavioral Neuroscience, 2016, 10, 170.	1.0	17
257	Astrocyte Differentiation of Human Pluripotent Stem Cells: New Tools for Neurological Disorder Research. Frontiers in Cellular Neuroscience, 2016, 10, 215.	1.8	120
258	Tau Protein Hyperphosphorylation and Aggregation in Alzheimerâ€™s Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules, 2016, 6, 6.	1.8	503
259	The Rationale for Insulin Therapy in Alzheimerâ€™s Disease. Molecules, 2016, 21, 689.	1.7	14
260	Peripheral Inflammation and Alzheimerâ€™s Disease: Periodontal Disease. , 2016, , 93-106.		0
261	APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations. Annals of Neurology, 2016, 79, 758-774.	2.8	77
262	Common and Rare Genetic Variants Associated With Alzheimer's Disease. Journal of Cellular Physiology, 2016, 231, 1432-1437.	2.0	12
263	Apolipoprotein É›4 is Associated with Dementia and Cognitive Impairment Predominantly Due to Alzheimerâ€™s Disease and Not with Vascular Cognitive Impairment: A Singapore-Based Cohort. Journal of Alzheimer's Disease, 2016, 51, 1111-1118.	1.2	19
264	Integration of transcriptomic and genomic data suggests candidate mechanisms for APOE4-mediated pathogenic action in Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 32583.	1.6	19
265	Is ApoE É› 4 a good biomarker for amyloid pathology in late onset Alzheimerâ€™s disease?. Translational Neurodegeneration, 2016, 5, 20.	3.6	15
266	Study of Exosomes Shed New Light on Physiology of Amyloidogenesis. Cellular and Molecular Neurobiology, 2016, 36, 327-342.	1.7	13
267	Identification and in Vivo Evaluation of Liver X Receptor Î²-Selective Agonists for the Potential Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2016, 59, 3489-3498.	2.9	38
268	Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics. Annual Review of Neuroscience, 2016, 39, 57-79.	5.0	97
269	New Genetic Links Between Alzheimer Disease and Immune-Mediated Diseases Revealed by Overlapping Genome-wide Association Study Hits. JAMA Neurology, 2016, 73, 638.	4.5	2
270	Pharmacological Chaperones: Design and Development of New Therapeutic Strategies for the Treatment of Conformational Diseases. ACS Chemical Biology, 2016, 11, 1471-1489.	1.6	85
271	Risk-reducing Apolipoprotein E and Clusterin genotypes protect against the consequences of poor vascular health on executive function performance and change in nondemented older adults. Neurobiology of Aging, 2016, 42, 91-100.	1.5	19
272	Genomics of Alzheimer Disease. JAMA Neurology, 2016, 73, 867.	4.5	105

#	Article	IF	Citations
273	Quercetin stabilizes apolipoprotein E and reduces brain AÎ² levels in amyloid model mice. Neuropharmacology, 2016, 108, 179-192.	2.0	52
274	A randomized controlled study to evaluate the effect of bexarotene on amyloidâ€Î² and apolipoprotein E metabolism in healthy subjects. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 110-120.	1.8	51
275	The Complex Role of Apolipoprotein E in Alzheimerâ€™s Disease: an Overview and Update. Journal of Molecular Neuroscience, 2016, 60, 325-335.	1.1	64
276	Relative effect of APOE Îµ4 on neuroimaging biomarker changes across the lifespan. Neurology, 2016, 87, 1696-1703.	1.5	44
277	Genetic Restoration of Plasma ApoE Improves Cognition and Partially Restores Synaptic Defects in ApoE-Deficient Mice. Journal of Neuroscience, 2016, 36, 10141-10150.	1.7	81
278	The Neurobiology and Age-Related Prevalence of the Îµ4 Allele of Apolipoprotein E in Alzheimerâ€™s Disease Cohorts. Journal of Molecular Neuroscience, 2016, 60, 316-324.	1.1	82
279	The amyloid hypothesis of Alzheimer's disease at 25Âyears. EMBO Molecular Medicine, 2016, 8, 595-608.	3.3	4,226
280	Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10186-10191.	3.3	179
281	Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse. Journal of Neuroscience, 2016, 36, 8653-8667.	1.7	177
282	Interactions between inflammation, sex steroids, and Alzheimerâ€™s disease risk factors. Frontiers in Neuroendocrinology, 2016, 43, 60-82.	2.5	81
283	TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron, 2016, 91, 328-340.	3.8	643
284	Genetic and degenerative disorders primarily causing dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 525-564.	1.0	5
285	The endocytic pathway in microglia during health, aging and Alzheimerâ€™s disease. Ageing Research Reviews, 2016, 32, 89-103.	5.0	93
286	Effects of glucose and insulin on secretion of amyloidâ€Î² by human adipose tissue cells. Obesity, 2016, 24, 1471-1479.	1.5	18
287	The Genetic Basis of Alzheimer's Disease. , 2016, , 547-571.		5
288	Increased amyloidogenic APP processing in APOE É›4-negative individuals with cerebral Î²-amyloidosis. Nature Communications, 2016, 7, 10918.	5.8	48
289	Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review. Atherosclerosis, 2016, 255, 145-155.	0.4	85
290	Orexin signaling regulates both the hippocampal clock and the circadian oscillation of Alzheimerâ€™s disease-risk genes. Scientific Reports, 2016, 6, 36035.	1.6	53

#	Article	IF	Citations
291	Human Central Nervous System (CNS) ApoE Isoforms Are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared with Plasma. Journal of Biological Chemistry, 2016, 291, 27204-27218.	1.6	42
292	Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease. Current Opinion in Lipidology, 2017, 28, 60-67.	1.2	123
293	Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. Neurobiology of Aging, 2016, 44, 159-172.	1.5	59
294	The Complex Pathways to Mechanism-Based Therapeutics in Alzheimerâ€™s Disease. , 2016, , 1-22.		0
295	The Genetic Basis of Alzheimerâ€™s Disease. , 2016, , 23-37.		5
296	Bloodâ€“Brain Barrier Transport of Alzheimerâ€™s Amyloid Î²-Peptide. , 2016, , 251-270.		5
297	Alzheimerâ€™s Disease Therapeutics Targeting Apolipoprotein E. , 2016, , 271-303.		0
298	Prospects and Challenges for Alzheimer Therapeutics. , 2016, , 605-637.		2
299	The Effect of the APOE4 Gene on Accumulation of AÎ² 40 After Brain Injury Cannot Be Reversed by Increasing apoE4 Protein. Journal of Neuropathology and Experimental Neurology, 2016, 75, 770-778.	0.9	10
300	Apolipoprotein E as a Therapeutic Target in Alzheimerâ€™s Disease: A Review of Basic Research and Clinical Evidence. CNS Drugs, 2016, 30, 773-789.	2.7	93
301	Active Immunization Against the Amyloid-Î² Peptide. Methods in Pharmacology and Toxicology, 2016, , 19-35.	0.1	0
302	Genetic variants associated with neurodegenerative Alzheimer disease in natural models. Biological Research, 2016, 49, 14.	1.5	27
303	Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. Journal of Molecular Medicine, 2016, 94, 739-746.	1.7	328
304	Nrf2 activation in the treatment of neurodegenerative diseases: a focus on its role in mitochondrial bioenergetics and function. Biological Chemistry, 2016, 397, 383-400.	1.2	128
305	Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells. Molecular and Cellular Neurosciences, 2016, 73, 13-31.	1.0	100
306	Alzheimer's disease genes and autophagy. Brain Research, 2016, 1649, 201-209.	1.1	40
307	The role of APOE in cerebrovascular dysfunction. Acta Neuropathologica, 2016, 131, 709-723.	3.9	161
308	Apolipoprotein E (APOE) Îµ4 and episodic memory decline in Alzheimerâ€™s disease: A review. Ageing Research Reviews, 2016, 27, 15-22.	5.0	70

#	Article	IF	Citations
309	Association of APOE with tau-tangle pathology with and without Î²-amyloid. Neurobiology of Aging, 2016, 37, 19-25.	1.5	97
310	Alzheimer's disease. Lancet, The, 2016, 388, 505-517.	6.3	2,430
311	Dendritic Spine Pathology in Neurodegenerative Diseases. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 221-250.	9.6	161
312	Alzheimerâ€™s Disease and the Sleepâ€“Wake Cycle. , 2016, , 295-317.		0
313	Changes in astrocyte functional markers and Î²-amyloid metabolism-related proteins in the early stages of hypercholesterolemia. Neuroscience, 2016, 316, 178-191.	1.1	37
314	Potential of tocotrienols in the prevention and therapy of Alzheimer's disease. Journal of Nutritional Biochemistry, 2016, 31, 1-9.	1.9	33
315	Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimerâ€™s Disease Spectrum. Molecular Neurobiology, 2016, 53, 4539-4547.	1.9	46
316	Dissecting Complex and Multifactorial Nature of Alzheimerâ€™s Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective. Molecular Neurobiology, 2016, 53, 4833-4864.	1.9	52
317	ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice. Journal of NeuroImmune Pharmacology, 2016, 11, 61-72.	2.1	49
318	Endogenous Apolipoprotein E (ApoE) Fragmentation Is Linked to Amyloid Pathology in Transgenic Mouse Models of Alzheimerâ€™s Disease. Molecular Neurobiology, 2017, 54, 319-327.	1.9	26
319	Monoaminergic neuropathology in Alzheimerâ€™s disease. Progress in Neurobiology, 2017, 151, 101-138.	2.8	206
320	ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and AÎ² Secretion. Cell, 2017, 168, 427-441.e21.	13.5	372
321	Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E Îµ4 Carriers. JAMA Neurology, 2017, 74, 339.	4.5	111
322	Cerebrospinal Fluid Proteins as Regulators of Betaâ€amyloid Aggregation and Toxicity. Israel Journal of Chemistry, 2017, 57, 602-612.	1.0	17
323	Altered cerebral insulin response in transgenic mice expressing the epsilon-4 allele of the human apolipoprotein E gene. Psychoneuroendocrinology, 2017, 77, 203-210.	1.3	13
324	ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease. Trends in Endocrinology and Metabolism, 2017, 28, 273-284.	3.1	112
325	Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load. Neurology, 2017, 88, 569-576.	1.5	50
326	Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Translational Psychiatry, 2017, 7, e995-e995.	2.4	56

#	Article	IF	Citations
327	Dysregulation of lipids in Alzheimer's disease and their role as potential biomarkers. Alzheimer's and Dementia, 2017, 13, 810-827.	0.4	146
328	Clearance of cerebral AÎ² in Alzheimerâ€™s disease: reassessing the role of microglia and monocytes. Cellular and Molecular Life Sciences, 2017, 74, 2167-2201.	2.4	199
329	Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-Î² Concentrations and Cognition Outcomes inÂAlzheimerâ€™s Disease Patients: AÂMulticenter, Randomized, Controlled Clinical Trial. Journal of Alzheimer's Disease, 2017, 56, 129-143.	1.2	67
330	Therapeutic potential of nuclear receptor agonists in Alzheimer's disease. Journal of Lipid Research, 2017, 58, 1937-1949.	2.0	61
331	Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?. Blood Reviews, 2017, 31, 261-270.	2.8	19
332	Islet amyloid polypeptide: Another key molecule in Alzheimerâ€™s pathogenesis?. Progress in Neurobiology, 2017, 153, 100-120.	2.8	64
333	Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-Î² and other amyloidogenic proteins. Journal of Lipid Research, 2017, 58, 824-836.	2.0	159
334	The role of APOE on lipid homeostasis and inflammation in normal brains. Journal of Lipid Research, 2017, 58, 1493-1499.	2.0	105
335	Evidence of oxidative stress and mitochondrial dysfunction in spinocerebellar ataxia type 2 (SCA2) patient fibroblasts: Effect of coenzyme Q10 supplementation on these parameters. Mitochondrion, 2017, 34, 103-114.	1.6	42
336	EFAD transgenic mice as a human APOE relevant preclinical model of AlzheimerÅ‰s disease. Journal of Lipid Research, 2017, 58, 1733-1755.	2.0	56
337	Update on Alzheimerâ€™s and the Dementias. Neurologic Clinics, 2017, 35, 171-174.	0.8	10
338	Dual-functional nanoparticles for precise drug delivery to Alzheimerâ€™s disease lesions: Targeting mechanisms, pharmacodynamics and safety. International Journal of Pharmaceutics, 2017, 525, 237-248.	2.6	53
339	Cholesterol as a modifying agent of the neurovascular unit structure and function under physiological and pathological conditions. Metabolic Brain Disease, 2017, 32, 935-948.	1.4	34
340	Recent Progress in Alzheimerâ€™s Disease Research, Part 2: Genetics and Epidemiology. Journal of Alzheimer's Disease, 2017, 57, 317-330.	1.2	131
341	Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. Nature, 2017, 544, 488-492.	13.7	317
342	Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Science Translational Medicine, 2017, 9, .	5.8	78
343	Elevated Plasma AÎ²42 in Cognitively Impaired Individuals Taking ACE Inhibitor Antihypertensives. American Journal of Alzheimer's Disease and Other Dementias, 2017, 32, 347-352.	0.9	9
344	Platelet cytochrome oxidase and citrate synthase activities in APOE Îµ4 carrier and non-carrier Alzheimer's disease patients. Redox Biology, 2017, 12, 828-832.	3.9	39

#	Article	IF	Citations
345	State of Play in Alzheimerâ€™s Disease Genetics. Journal of Alzheimer's Disease, 2017, 58, 631-659.	1.2	34
346	A Unique Microglia Type Associated with Restricting Development of Alzheimerâ€™s Disease. Cell, 2017, 169, 1276-1290.e17.	13.5	3,282
347	Co-injection of AÎ²1-40 and ApoE4 impaired spatial memory and hippocampal long-term potentiation in rats. Neuroscience Letters, 2017, 648, 47-52.	1.0	5
348	Microglial complement receptor 3 regulates brain AÎ² levels through secreted proteolytic activity. Journal of Experimental Medicine, 2017, 214, 1081-1092.	4.2	100
349	Alzheimerâ€™s disease: experimental models and reality. Acta Neuropathologica, 2017, 133, 155-175.	3.9	513
350	Young microglia restore amyloid plaque clearance of aged microglia. EMBO Journal, 2017, 36, 583-603.	3.5	124
351	Molecular Genetics of Neurodegenerative Dementias. Cold Spring Harbor Perspectives in Biology, 2017, 9, a023705.	2.3	51
352	Genetic influences on cognition in progressive supranuclear palsy. Movement Disorders, 2017, 32, 1764-1771.	2.2	6
353	Circadian wheel running behavior is altered in an APP/E4 mouse model of late onset Alzheimer's disease. Physiology and Behavior, 2017, 182, 137-142.	1.0	13
354	Endosomal Traffic Jams Represent a Pathogenic Hub and Therapeutic Target in Alzheimerâ€™s Disease. Trends in Neurosciences, 2017, 40, 592-602.	4.2	114
355	Effect of apolipoprotein E phenotype on the association of plasma amyloidÂÎ² and amyloid positron emission tomography imaging in Japan. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 51-56.	1.2	7
356	Genetic underpinnings in Alzheimerâ€™s disease â€“ a review. Reviews in the Neurosciences, 2017, 29, 21-38.	1.4	25
357	Alzheimerâ€™s disease: A matter of bloodâ€“brain barrier dysfunction?. Journal of Experimental Medicine, 2017, 214, 3151-3169.	4.2	467
358	Amyloidogenesis of Tau protein. Protein Science, 2017, 26, 2126-2150.	3.1	102
359	Targeting Apolipoprotein E/Amyloid Î² Binding by Peptoid CPO_AÎ²17-21â€‰P Ameliorates Alzheimerâ€™s Disease Related Pathology and Cognitive Decline. Scientific Reports, 2017, 7, 8009.	1.6	47
360	Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid. NeuroImage: Clinical, 2017, 16, 418-428.	1.4	23
361	Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. Scientific Reports, 2017, 7, 9766.	1.6	59
362	ApoE4 Accelerates Early Seeding of Amyloid Pathology. Neuron, 2017, 96, 1024-1032.e3.	3.8	258

#	Article	IF	Citations
363	Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of Î²-amyloidosis. Neuron, 2017, 96, 1013-1023.e4.	3.8	134
364	ABC Transporters Are Key Players in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 61, 463-485.	1.2	57
365	Tau Phosphorylation and Amyloid-Î² Deposition in the Presence of Formaldehyde. , 2017, , 167-189.		0
366	Genetics of Alzheimer's disease: an update. Future Neurology, 2017, 12, 237-247.	0.9	0
367	Neuronal hyperactivity due to loss of inhibitory tone in APOE4 mice lacking Alzheimerâ€™s disease-like pathology. Nature Communications, 2017, 8, 1464.	5.8	122
368	Animal Models of Alzheimerâ€™s Disease. , 2017, , 1031-1085.		9
369	Neuropathologic features of TOMM40 '523 variant on lateâ€life cognitive decline. Alzheimer's and Dementia, 2017, 13, 1380-1388.	0.4	14
370	Glial contributions to neurodegeneration in tauopathies. Molecular Neurodegeneration, 2017, 12, 50.	4.4	283
371	The Alzheimerâ€™s disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway. Journal of Neuroinflammation, 2017, 14, 59.	3.1	59
372	APOE Genotype Differentially Modulates Effects of Anti-AÎ², Passive Immunization in APP Transgenic Mice. Molecular Neurodegeneration, 2017, 12, 12.	4.4	25
373	The application of lipidomics to biomarker research and pathomechanisms in Alzheimer's disease. Current Opinion in Psychiatry, 2017, 30, 136-144.	3.1	29
374	Disordered APP metabolism and neurovascular in trauma and aging: Combined risks for chronic neurodegenerative disorders. Ageing Research Reviews, 2017, 34, 51-63.	5.0	41
376	The apolipoprotein E gene affects the three-year trajectories of compensatory neural processes in the left-lateralized hippocampal network. Brain Imaging and Behavior, 2017, 11, 1446-1458.	1.1	20
377	Increased intermediate M1â€M2 macrophage polarization and improved cognition in mild cognitive impairment patients on Ï‰â€3 supplementation. FASEB Journal, 2017, 31, 148-160.	0.2	72
378	Animal Models of Alzheimerâ€™s Disease. , 2017, , 31-58.		1
379	Ligands of Therapeutic Utility for the Liver X Receptors. Molecules, 2017, 22, 88.	1.7	67
380	Amyloid Î² Hypothesis in the Development of Therapeutic Agents for Alzheimerâ€™s Disease. , 2017, , 109-143.		5
381	Milkâ€™s Role as an Epigenetic Regulator in Health and Disease. Diseases (Basel, Switzerland), 2017, 5, 12.	1.0	95

#	Article	IF	Citations
382	Lipid Processing in the Brain: A Key Regulator of Systemic Metabolism. Frontiers in Endocrinology, 2017, 8, 60.	1.5	155
383	The Endosomalâ€“Lysosomal Pathway Is Dysregulated by APOE4 Expression in Vivo. Frontiers in Neuroscience, 2017, 11, 702.	1.4	90
384	Functional Roles of the Interaction of APP and Lipoprotein Receptors. Frontiers in Molecular Neuroscience, 2017, 10, 54.	1.4	58
385	APP Function and Lipids: A Bidirectional Link. Frontiers in Molecular Neuroscience, 2017, 10, 63.	1.4	76
386	Alzheimerâ€™s Disease: From Genetic Variants to the Distinct Pathological Mechanisms. Frontiers in Molecular Neuroscience, 2017, 10, 319.	1.4	35
387	Building a better blood-brain barrier. ELife, 2017, 6, .	2.8	3
388	Preclinical effects of APOE Îµ4 on cerebrospinal fluid AÎ²42 concentrations. Alzheimer's Research and Therapy, 2017, 9, 87.	3.0	22
389	Obesity Accelerates Alzheimer-Related Pathology inAPOE4but notAPOE3Mice. ENeuro, 2017, 4, ENEURO.0077-17.2017.	0.9	70
390	Prions. , 2018, , .		0
391	Brain insulin signalling, glucose metabolism and females' reproductive aging: A dangerous triad in Alzheimer's disease. Neuropharmacology, 2018, 136, 223-242.	2.0	38
392	Differential Effect of APOE É›4 Status and Elevated Pulse Pressure on Functional Decline in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2018, 62, 1567-1578.	1.2	6
393	APOE genotype modifies the association between central arterial stiffening and cognition in older adults. Neurobiology of Aging, 2018, 67, 120-127.	1.5	16
394	Determining the Potential of Mean Force for Amyloid-Î² Dimerization: Combining Self-Consistent Field Theory with Molecular Dynamics Simulation. Journal of Chemical Theory and Computation, 2018, 14, 2696-2704.	2.3	16
395	Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nature Medicine, 2018, 24, 647-657.	15.2	288
396	Î²-Amyloid accumulation in the human brain after one night of sleep deprivation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4483-4488.	3.3	571
397	Amyloid toxicity in Alzheimerâ€™s disease. Reviews in the Neurosciences, 2018, 29, 613-627.	1.4	312
398	AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. Human Gene Therapy Clinical Development, 2018, 29, 24-47.	3.2	90
399	Sifting through a failed Alzheimer trial. Neurology, 2018, 90, 447-448.	1.5	6

#	Article	IF	Citations
400	Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 65, 781-791.	1.2	25
401	Genetic Modifiers in Neurodegeneration. Current Genetic Medicine Reports, 2018, 6, 11-19.	1.9	11
402	DNA methylation of TOMM40-APOE-APOC2 in Alzheimerâ€™s disease. Journal of Human Genetics, 2018, 63, 459-471.	1.1	57
403	Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. Journal of Alzheimer's Disease, 2018, 62, 1223-1240.	1.2	150
404	Haplotype analysis of APOE intragenic SNPs. BMC Neuroscience, 2018, 19, 16.	0.8	43
405	Impact of late-onset Alzheimerâ€™s genetic risk factors on beta-amyloid endocytic production. Cellular and Molecular Life Sciences, 2018, 75, 2577-2589.	2.4	37
406	Genetic Risk Factors for Complex Forms of Alzheimerâ€™s Disease. , 2018, , 51-76.		0
407	Potential Novel Approaches to Understand the Pathogenesis and Treat Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, S299-S312.	1.2	22
408	Epigenetics in Alzheimerâ€™s Disease: Perspective of DNA Methylation. Molecular Neurobiology, 2018, 55, 1026-1044.	1.9	96
409	Apolipoprotein E, Receptors, and Modulation of Alzheimerâ€™s Disease. Biological Psychiatry, 2018, 83, 347-357.	0.7	265
410	AÎ² propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease. Neurobiology of Disease, 2018, 109, 191-200.	2.1	57
411	Untangling Genetic Risk for Alzheimerâ€™s Disease. Biological Psychiatry, 2018, 83, 300-310.	0.7	160
412	Decreasing hazards of <scp>Alzheimer</scp>'s disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein <scp>E</scp>. International Journal of Geriatric Psychiatry, 2018, 33, 200-211.	1.3	27
413	Microglia-Mediated Neuroprotection, TREM2 , and Alzheimerâ€™s Disease: Evidence From OpticalÂImaging. Biological Psychiatry, 2018, 83, 377-387.	0.7	84
414	Risk factors for amyloid positivity in older people reporting significant memory concern. Comprehensive Psychiatry, 2018, 80, 126-131.	1.5	10
415	Peptides isolated from animal venom as a platform for new therapeutics for the treatment of Alzheimer's disease. Neuropeptides, 2018, 67, 79-86.	0.9	12
416	Microglia in Alzheimerâ€™s disease. Journal of Cell Biology, 2018, 217, 459-472.	2.3	1,188
417	Hidden heterogeneity in Alzheimer's disease: Insights from genetic association studies and other analyses. Experimental Gerontology, 2018, 107, 148-160.	1.2	45

#	Article	IF	Citations
418	Exploring APOE genotype effects on Alzheimer's disease risk and amyloid Î² burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results. Alzheimer's and Dementia, 2018, 14, 634-643.	0.4	33
419	The pleiotropic vasoprotective functions of high density lipoproteins (HDL). Journal of Biomedical Research, 2018, 32, .	0.7	23
420	All (animal) models (of neurodegeneration) are wrong. Are they also useful?. Journal of Experimental Medicine, 2018, 215, 2955-2958.	4.2	54
421	Risk Factors and Pathogenesis of HIV-Associated Neurocognitive Disorder: The Role of Host Genetics. International Journal of Molecular Sciences, 2018, 19, 3594.	1.8	48
422	Deletion of plasmaPhospholipid Transfer Protein (PLTP)increases microglial phagocytosis and reduces cerebral amyloid-Î² deposition in the J20 mouse model of Alzheimer's disease. Oncotarget, 2018, 9, 19688-19703.	0.8	10
423	RAB10: an Alzheimer’s disease resilience locus and potential drug target. Clinical Interventions in Aging, 2019, Volume 14, 73-79.	1.3	37
424	Effects of APOE Genotype on Brain Proteomic Network and Cell Type Changes in Alzheimer's Disease. Frontiers in Molecular Neuroscience, 2018, 11, 454.	1.4	55
425	New insights into the role of TREM2 in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2018, 13, 66.	4.4	286
426	Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimerâ€™s disease â€“conformist, nonconformist, and realistic prospects for AD pathogenesis. Translational Neurodegeneration, 2018, 7, 34.	3.6	77
427	Advances in developing novel therapeutic strategies for Alzheimerâ€™s disease. Molecular Neurodegeneration, 2018, 13, 64.	4.4	189
428	In Vivo Microdialysis Method to Collect Large Extracellular Proteins from Brain Interstitial Fluid with High-molecular Weight Cut-off Probes. Journal of Visualized Experiments, 2018, , .	0.2	7
429	Alzheimerâ€™s disease (AD) therapeutics â€“ 2: Beyond amyloid â€“ Re-defining AD and its causality to discover effective therapeutics. Biochemical Pharmacology, 2018, 158, 376-401.	2.0	24
430	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	1.2	12
431	Apolipoprotein E, cognitive function, and cognitive decline among older Taiwanese adults. PLoS ONE, 2018, 13, e0206118.	1.1	16
432	The <scp>BACE</scp> â€1 inhibitor <scp>CNP</scp> 520 for prevention trials in Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	3.3	112
433	Absolute 10-year risk of dementia by age, sex and APOE genotype: a population-based cohort study. Cmaj, 2018, 190, E1033-E1041.	0.9	71
434	Relationship Between Amyloid-Î² Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1313-1325.	1.2	19
435	Higher Blood Vitamin C Levels are Associated with Reduction of Apolipoprotein E E4-related Risks of Cognitive Decline in Women: The Nakajima Study. Journal of Alzheimer's Disease, 2018, 63, 1289-1297.	1.2	15

#	Article	IF	Citations
436	Patterns and severity of vascular amyloid in Alzheimerâ€™s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimerâ€™s disease. Acta Neuropathologica, 2018, 136, 569-587.	3.9	47
437	APOEâ€Îµ4 associates with hippocampal volume, learning, and memory across the spectrum of Alzheimer's disease and dementia with Lewy bodies. Alzheimer's and Dementia, 2018, 14, 1137-1147.	0.4	39
438	Brain APOE expression quantitative trait loci-based association study identified one susceptibility locus for Alzheimerâ€™s disease by interacting with APOE Îµ4. Scientific Reports, 2018, 8, 8068.	1.6	16
439	Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6640-E6649.	3.3	129
440	Trisomy of human chromosome 21 enhances amyloid-Î² deposition independently of an extra copy ofAPP. Brain, 2018, 141, 2457-2474.	3.7	96
441	The Level of Plasma Amyloid-Î²40 Is Correlated with Peripheral Transport Proteins in Cognitively Normal Adults: A Population-Based Cross-Sectional Study. Journal of Alzheimer's Disease, 2018, 65, 951-961.	1.2	9
442	Molecular Mechanisms for Herpes Simplex Virus Type 1 Pathogenesis in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 48.	1.7	116
443	Deciphering the Astrocyte Reaction in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 114.	1.7	202
444	Cellular Receptors of Amyloid Î² Oligomers (AÎ²Os) in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2018, 19, 1884.	1.8	66
445	Genetic variants associated with Alzheimerâ€™s disease confer different cerebral cortex cell-type population structure. Genome Medicine, 2018, 10, 43.	3.6	62
446	Modelling Alzheimer's disease: Insights fromin vivotoin vitrothree-dimensional culture platforms. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 1944-1958.	1.3	18
447	Modulating Early Stage Amyloid Aggregates by Dipeptide-Linked Perylenebisimides: Structureâ€“Activity Relationship, Inhibition of Fibril Formation in Human CSF and AÎ²1â€“40. ACS Applied Bio Materials, 2018, 1, 403-413.	2.3	3
448	Do Cardiometabolic Risk Factors Influence Amyloid, Tau, and Neuronal Function in APOE4 Carriers and Non-Carriers in Alzheimerâ€™s Disease Trajectory?. Journal of Alzheimer's Disease, 2018, 64, 981-993.	1.2	11
449	ApoE isoforms and carboxyl-terminal-truncated apoE4 forms affect neuronal BACE1 levels and AÎ² production independently of their cholesterol efflux capacity. Biochemical Journal, 2018, 475, 1839-1859.	1.7	19
450	Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nature Reviews Immunology, 2018, 18, 759-772.	10.6	394
451	Prophylactic and Therapeutic Applications of Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimerâ€™s Disease. , 2018, , 139-161.		1
452	Association between apolipoprotein E genotypes and panic disorder in Turkish population. Nordic Journal of Psychiatry, 2018, 72, 477-483.	0.7	0
453	Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases. FEBS Journal, 2018, 285, 3631-3644.	2.2	98

#	Article	IF	Citations
454	Activities of mitochondrial respiratory chain complexes in platelets of patients with Alzheimer's disease and depressive disorder. Mitochondrion, 2019, 48, 67-77.	1.6	40
455	Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nature Reviews Neurology, 2019, 15, 501-518.	4.9	734
456	Alzheimerâ€™s in a dish â€“ induced pluripotent stem cell-based disease modeling. Translational Neurodegeneration, 2019, 8, 21.	3.6	23
457	Vitamin E and Alzheimerâ€™s disease: what do we know so far? . Clinical Interventions in Aging, 2019, Volume 14, 1303-1317.	1.3	74
459	Elucidating the Role of Apolipoprotein E Isoforms in Spinal Cord Injury-Associated Neuropathology. Journal of Neurotrauma, 2019, 36, 3317-3322.	1.7	8
460	Current and emerging avenues for Alzheimer's disease drug targets. Journal of Internal Medicine, 2019, 286, 398-437.	2.7	102
461	Highâ€affinity multivalent interactions between apolipoprotein E and the oligomers of amyloidâ€Î². FEBS Journal, 2019, 286, 4737-4753.	2.2	25
462	Targeting apolipoprotein E for treating Alzheimerâ€™s disease. Neuroscience Letters, 2019, 709, 134366.	1.0	6
463	Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk. Journal of Neuroscience, 2019, 39, 7408-7427.	1.7	85
464	Non-coding variability at the APOE locus contributes to the Alzheimerâ€™s risk. Nature Communications, 2019, 10, 3310.	5.8	91
465	Lack of hepatic apoE does not influence early AÎ² deposition: observations from a new APOE knock-in model. Molecular Neurodegeneration, 2019, 14, 37.	4.4	76
466	High-Throughput Mass Spectrometry Assay for Quantifying Î²-Amyloid 40 and 42 in Cerebrospinal Fluid. Clinical Chemistry, 2019, 65, 1572-1580.	1.5	17
467	The Role of Physical Fitness in Cognitive-Related Biomarkers in Persons at Genetic Risk of Familial Alzheimerâ€™s Disease. Journal of Clinical Medicine, 2019, 8, 1639.	1.0	10
468	Future horizons in Alzheimer's disease research. Progress in Molecular Biology and Translational Science, 2019, 168, 223-241.	0.9	19
469	Prionoid Proteins in the Pathogenesis of Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2019, 12, 271.	1.4	26
470	APOE Genotype Differentially Modulates Plasma Lipids in Healthy Older Individuals, with Relevance to Brain Health. Journal of Alzheimer's Disease, 2019, 72, 703-716.	1.2	13
471	Persistent Infection with Herpes Simplex Virus 1 and Alzheimerâ€™s Diseaseâ€”A Call to Study How Variability in Both Virus and Host may Impact Disease. Viruses, 2019, 11, 966.	1.5	28
472	Herpes simplex virus-1 (HSV-1) infection induces a potent but ineffective IFN-Î» production in immune cells of AD and PD patients. Journal of Translational Medicine, 2019, 17, 286.	1.8	14

#	Article	IF	Citations
473	Association between Apolipoprotein E Gene Polymorphism and Alzheimer's Disease in an Iranian Population: A Meta-Analysis. Journal of Molecular Neuroscience, 2019, 69, 557-562.	1.1	25
474	Extra-virgin olive oil for potential prevention of Alzheimer disease. Revue Neurologique, 2019, 175, 705-723.	0.6	51
475	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell, 2019, 179, 312-339.	13.5	1,675
476	Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities. Frontiers in Aging Neuroscience, 2019, 11, 233.	1.7	228
477	Sex Differences in the Genetic Architecture of Alzheimerâ€™s Disease. Current Genetic Medicine Reports, 2019, 7, 13-21.	1.9	24
478	Apolipoprotein E Polymorphism and Oxidative Stress in Peripheral Blood-Derived Macrophage-Mediated Amyloid-Beta Phagocytosis in Alzheimerâ€™s Disease Patients. Cellular and Molecular Neurobiology, 2019, 39, 355-369.	1.7	19
479	APOE Genotype Specific Effects on the Early Neurodegenerative Sequelae Following Chronic Repeated Mild Traumatic Brain Injury. Neuroscience, 2019, 404, 297-313.	1.1	25
480	The Promises and Challenges of Erythropoietin for Treatment of Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2019, 21, 12-24.	1.8	37
481	Influence of Matrix Metallopeptidase 9 on Beta-Amyloid Elimination Across the Blood-Brain Barrier. Molecular Neurobiology, 2019, 56, 8296-8305.	1.9	19
482	SILK studies â€" capturing the turnover of proteins linked to neurodegenerative diseases. Nature Reviews Neurology, 2019, 15, 419-427.	4.9	37
483	APOE Effect on Amyloid-Î² PET Spatial Distribution, Deposition Rate, and Cut-Points. Journal of Alzheimer's Disease, 2019, 69, 783-793.	1.2	15
484	Alzheimer disease and aducanumab: adjusting our approach. Nature Reviews Neurology, 2019, 15, 365-366.	4.9	154
485	Effects ofin vivoconditions on amyloid aggregation. Chemical Society Reviews, 2019, 48, 3946-3996.	18.7	148
486	Apolipoprotein E4, inhibitory network dysfunction, and Alzheimerâ€™s disease. Molecular Neurodegeneration, 2019, 14, 24.	4.4	111
487	Contribution of astrocytes to metabolic dysfunction in the Alzheimerâ€™s disease brain. Biological Chemistry, 2019, 400, 1113-1127.	1.2	31
488	Atomic resolution map of the soluble amyloid beta assembly toxic surfaces. Chemical Science, 2019, 10, 6072-6082.	3.7	48
489	Apolipoprotein E/Amyloid-Î² Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4. American Journal of Pathology, 2019, 189, 1621-1636.	1.9	35
490	The role of APOE4 in Alzheimerâ€™s disease: strategies for future therapeutic interventions. Neuronal Signaling, 2019, 3, NS20180203.	1.7	31

#	Article	IF	Citations
491	Regulating effect of CBF on memory in cognitively normal older adults with different ApoE genotype: the Alzheimerâ€™s Disease Neuroimaging Initiative (ADNI). Cognitive Neurodynamics, 2019, 13, 513-518.	2.3	7
492	A Novel Apolipoprotein E Antagonist Functionally Blocks Apolipoprotein E Interaction With N-terminal Amyloid Precursor Protein, Reduces Î²-Amyloid-Associated Pathology, and Improves Cognition. Biological Psychiatry, 2019, 86, 208-220.	0.7	29
494	Age-Associated Changes in the Immune System and Bloodâ€“Brain Barrier Functions. International Journal of Molecular Sciences, 2019, 20, 1632.	1.8	107
495	Proteomic Profiles of the Early Mitochondrial Changes in APP/PS1 and ApoE4 Transgenic Mice Models of Alzheimerâ€™s Disease. Journal of Proteome Research, 2019, 18, 2632-2642.	1.8	18
496	A Quarter Century of APOE and Alzheimerâ€™s Disease: Progress to Date and the Path Forward. Neuron, 2019, 101, 820-838.	3.8	338
497	ApoE and clusterin CSF levels influence associations between APOEÂgenotype and changes in CSF tau, but not CSF AÎ²42, levels inÂnon-demented elderly. Neurobiology of Aging, 2019, 79, 101-109.	1.5	12
498	Choroid Plexus Acts as Gatekeeper for TREM2, Abnormal Accumulation of ApoE, and Fibrillary Tau in Alzheimerâ€™s Disease and in Down Syndrome Dementia. Journal of Alzheimer's Disease, 2019, 69, 91-109.	1.2	31
499	Endo-lysosomal pathway and ubiquitin-proteasome system dysfunction in Alzheimer's disease pathogenesis. Neuroscience Letters, 2019, 703, 68-78.	1.0	56
500	Understanding the Amyloid Hypothesis in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 68, 493-510.	1.2	77
501	The Effectiveness of Vitamin E Treatment in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2019, 20, 879.	1.8	100
502	Genetic discoveries and advances in lateâ€onset Alzheimerâ€™s disease. Journal of Cellular Physiology, 2019, 234, 16873-16884.	2.0	14
503	Supraphysiologic-dose anabolicâ€“androgenic steroid use: A risk factor for dementia?. Neuroscience and Biobehavioral Reviews, 2019, 100, 180-207.	2.9	34
504	Effects of Microglial Cytokines on Alzheimerâ€™s Disease-Related Phenomena. Journal of Alzheimer's Disease, 2019, 67, 1021-1034.	1.2	7
505	Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimerâ€™s disease pathogenesis. Cellular and Molecular Life Sciences, 2019, 76, 1833-1863.	2.4	75
506	Decreased immunoglobulin G in brain regions of elder female APOE4-TR mice accompany with AÎ² accumulation. Immunity and Ageing, 2019, 16, 2.	1.8	13
507	Misidentification Subtype of Alzheimer's Disease Psychosis Predicts a Faster Cognitive Decline. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 308-315.	1.3	8
508	Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms. Advances in Experimental Medicine and Biology, 2019, 1118, 83-116.	0.8	34
509	The Role of Apolipoprotein E Isoforms in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 68, 459-471.	1.2	21

#	Article	IF	Citations
510	Î³-Secretase and its modulators: Twenty years and beyond. Neuroscience Letters, 2019, 701, 162-169.	1.0	46
511	ACE gene missense mutation in a case with early-onset, rapid progressing dementia. Annals of General Psychiatry, 2019, 32, e100028.	1.1	5
512	Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimerâ€™s disease. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641988881.	1.5	46
513	Neurophysiological Markers of Alzheimerâ€™s Disease: Quantitative EEG Approach. Neurology and Therapy, 2019, 8, 37-55.	1.4	60
514	The Role of APOE and TREM2 in Alzheimerâ€²s Diseaseâ€”Current Understanding and Perspectives. International Journal of Molecular Sciences, 2019, 20, 81.	1.8	123
515	Beyond the neuronâ€“cellular interactions early in Alzheimer disease pathogenesis. Nature Reviews Neuroscience, 2019, 20, 94-108.	4.9	237
516	Obstacles to translating the promise of nanoparticles into viable amyloid disease therapeutics. Physical Biology, 2019, 16, 021002.	0.8	2
517	Effects of apolipoprotein E on nutritional metabolism in dementia. Current Opinion in Lipidology, 2019, 30, 10-15.	1.2	13
518	Blood-Brain Barrier: From Physiology to Disease and Back. Physiological Reviews, 2019, 99, 21-78.	13.1	1,232
519	Is Fat Mass Cross-Sectionally Associated with Cortical AÎ² Load in the Human Brain?. Journal of Nutrition, Health and Aging, 2019, 23, 207-210.	1.5	1
520	Sleep and circadian rhythm disruption and stress intersect in Alzheimer's disease. Neurobiology of Stress, 2019, 10, 100133.	1.9	41
521	Nanotherapeutic strategies for the treatment of neurodegenerative diseases. , 2019, , 321-356.		14
522	Alzheimerâ€™s Disease and Dementia. , 2019, , 25-82.		2
523	Correlation between Apolipoprotein E genotype and brain metabolism in amyotrophic lateral sclerosis. European Journal of Neurology, 2019, 26, 306-312.	1.7	8
524	Rationale for the development of an Alzheimerâ€™s disease vaccine. Human Vaccines and Immunotherapeutics, 2020, 16, 645-653.	1.4	16
525	The interplay between agingâ€associated loss of protein homeostasis and extracellular vesicles in neurodegeneration. Journal of Neuroscience Research, 2020, 98, 262-283.	1.3	21
526	Regulation of Alzheimer's disease-associated proteins during epileptogenesis. Neuroscience, 2020, 424, 102-120.	1.1	7
527	Cholesterol and Dementia: A Long and Complicated Relationship. Current Aging Science, 2020, 13, 42-51.	0.4	22

#	Article	IF	Citations
528	Intracerebral Expression of AAV-APOE4 Is Not Sufficient to Alter Tau Burden in Two Distinct Models of Tauopathy. Molecular Neurobiology, 2020, 57, 1986-2001.	1.9	9
529	APOE in the normal brain. Neurobiology of Disease, 2020, 136, 104724.	2.1	84
530	Association of Apolipoprotein E Îµ4 With Medial Temporal Tau Independent of Amyloid-Î². JAMA Neurology, 2020, 77, 470.	4.5	154
531	Î²-Amyloid Peptide: the Cell Compartment Multi-faceted Interaction in Alzheimerâ€™s Disease. Neurotoxicity Research, 2020, 37, 250-263.	1.3	38
532	Enhanced amyloid-Î² generation by Î³-secretase complex in DRM microdomains with reduced cholesterol levels. Human Molecular Genetics, 2020, 29, 382-393.	1.4	5
533	Association of Low-Density Lipoprotein Receptor-Related Protein 1 and Its rs1799986 Polymorphism With Mild Cognitive Impairment in Chinese Patients With Type 2 Diabetes. Frontiers in Neuroscience, 2020, 14, 743.	1.4	6
534	Microglia in Alzheimerâ€™s Disease in the Context of Tau Pathology. Biomolecules, 2020, 10, 1439.	1.8	56
535	The role of glia in protein aggregation. Neurobiology of Disease, 2020, 143, 105015.	2.1	28
536	From beta amyloid to altered proteostasis in Alzheimerâ€™s disease. Ageing Research Reviews, 2020, 64, 101126.	5.0	31
537	Passive immunotherapies targeting AÎ² and tau in Alzheimer's disease. Neurobiology of Disease, 2020, 144, 105010.	2.1	81
538	Modulation of Î²-Amyloid Fibril Formation in Alzheimerâ€™s Disease by Microglia and Infection. Frontiers in Molecular Neuroscience, 2020, 13, 609073.	1.4	35
539	Nanobiosensors for Non-Amyloidbeta-Tau Biomarkers as Advanced Reporters of Alzheimerâ€™s Disease. Diagnostics, 2020, 10, 913.	1.3	1
540	Evaluating Circadian Dysfunction in Mouse Models of Alzheimerâ€™s Disease: Where Do We Stand?. Frontiers in Neuroscience, 2020, 14, 703.	1.4	15
541	Endosomal-Lysosomal Processing of Neurodegeneration-Associated Proteins in Astrocytes. International Journal of Molecular Sciences, 2020, 21, 5149.	1.8	12
542	Endosomal Acid-Base Homeostasis in Neurodegenerative Diseases. Reviews of Physiology, Biochemistry and Pharmacology, 2020, , 195-231.	0.9	4
543	The existence of AÎ² strains and their potential for driving phenotypic heterogeneity in Alzheimerâ€™s disease. Acta Neuropathologica, 2021, 142, 17-39.	3.9	35
544	Clusterin as a Potential Biomarker of Obesity-Related Alzheimerâ€™s Disease Risk. Biomarker Insights, 2020, 15, 117727192096410.	1.0	12
545	Delta-secretase cleavage of Tau mediates its pathology and propagation in Alzheimerâ€™s disease. Experimental and Molecular Medicine, 2020, 52, 1275-1287.	3.2	17

#	Article	IF	Citations
546	Highâ€density lipoproteinâ€related cholesterol metabolism in Alzheimerâ€™s disease. Journal of Neurochemistry, 2021, 159, 343-377.	2.1	8
547	Cerebral Small Vessel Disease and Alzheimer's Disease: A Review. Frontiers in Neurology, 2020, 11, 927.	1.1	53
548	Association between APOE Îµ2 and AÎ² burden in patients with Alzheimer- and vascular-type cognitive impairment. Neurology, 2020, 95, e2354-e2365.	1.5	4
549	Neuropathological correlates of cortical superficial siderosis in cerebral amyloid angiopathy. Brain, 2020, 143, 3343-3351.	3.7	46
550	Gene-Editing Technologies Paired With Viral Vectors for Translational Research Into Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2020, 13, 148.	1.4	20
551	Biomarkers for Alzheimerâ€™s Disease Early Diagnosis. Journal of Personalized Medicine, 2020, 10, 114.	1.1	58
552	Allelic Distribution of Genes for Apolipoprotein E and MTHFR in Patients with Alzheimerâ€™s Disease and Their Epistatic Interaction. Journal of Alzheimer's Disease, 2020, 77, 1095-1105.	1.2	3
553	Independent and Correlated Role of Apolipoprotein E É›4 Genotype and Herpes Simplex Virus Type 1 in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 77, 15-31.	1.2	4
554	Molecular Dysfunctions of Mitochondria-Associated Membranes (MAMs) in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 9521.	1.8	34
555	Lipids, brain ageing, dementia, and lipidomics. , 2020, , 183-205.		2
556	Effect of APOE Îµ4 genotype on amyloid-Î² and tau accumulation in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 140.	3.0	61
557	APOE2: protective mechanism and therapeutic implications for Alzheimerâ€™s disease. Molecular Neurodegeneration, 2020, 15, 63.	4.4	110
559	The Role of Synaptic Dysfunction inÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 76, 49-62.	1.2	13
560	Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study. Journal of Nuclear Medicine, 2020, 61, 1814-1819.	2.8	20
561	Proteomic Profiling of Plasma and Brain Tissue from Alzheimerâ€™s Disease Patients Reveals Candidate Network of Plasma Biomarkers. Journal of Alzheimer's Disease, 2020, 76, 349-368.	1.2	31
562	The Positive Side of the Alzheimerâ€™s Disease Amyloid Cross-Interactions: The Case of the AÎ² 1-42 Peptide with Tau, TTR, CysC, and ApoA1. Molecules, 2020, 25, 2439.	1.7	37
563	Lipid and Lipoprotein Metabolism in Microglia. Frontiers in Physiology, 2020, 11, 393.	1.3	122
564	Lipid efflux mechanisms, relation to disease and potential therapeutic aspects. Advanced Drug Delivery Reviews, 2020, 159, 54-93.	6.6	18

#	Article	IF	Citations
565	Amyloidogenic processing of amyloid Î² protein precursor (APP) is enhanced in the brains of alcadein Î±â€“deficient mice. Journal of Biological Chemistry, 2020, 295, 9650-9662.	1.6	11
566	A Role of Low-Density Lipoprotein Receptor-Related Protein 4 (LRP4) in Astrocytic AÎ² Clearance. Journal of Neuroscience, 2020, 40, 5347-5361.	1.7	35
567	Genetic architecture of Alzheimer's disease. Neurobiology of Disease, 2020, 143, 104976.	2.1	73
568	Simple and Fast Assay for Apolipoprotein E Phenotyping and Glycotyping: Discovering Isoform-Specific Glycosylation in Plasma and Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2020, 76, 883-893.	1.2	16
569	Mild Cognitive Impairment Staging Yields Genetic Susceptibility, Biomarker, and Neuroimaging Differences. Frontiers in Aging Neuroscience, 2020, 12, 139.	1.7	4
570	Revisiting the role of brain and peripheral AÎ² in the pathogenesis of Alzheimer's disease. Journal of the Neurological Sciences, 2020, 416, 116974.	0.3	48
571	Commentary: Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk. Frontiers in Aging Neuroscience, 2020, 12, 127.	1.7	1
572	APOE4 is Associated with Differential Regional Vulnerability to Bioenergetic Deficits in Aged APOE Mice. Scientific Reports, 2020, 10, 4277.	1.6	34
573	The effect of ApoE Îµ 4 on clinical and structural MRI markers in prodromal Alzheimerâ€™s disease. Quantitative Imaging in Medicine and Surgery, 2020, 10, 464-474.	1.1	13
574	Neuroinflammation drives APOE genotype-dependent differential expression of neprilysin. Journal of Neuroimmunology, 2020, 346, 577315.	1.1	7
575	Apolipoprotein E isoforms differentially regulate matrix metallopeptidase 9 function in Alzheimerâ€™s disease. Neurobiology of Aging, 2020, 95, 56-68.	1.5	13
576	Beta-amyloid deposition around hepatic bile ducts is a novel pathobiological and diagnostic feature of biliary atresia. Journal of Hepatology, 2020, 73, 1391-1403.	1.8	31
577	Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers. Chemical Society Reviews, 2020, 49, 5446-5472.	18.7	56
578	APOE-amyloid interaction: Therapeutic targets. Neurobiology of Disease, 2020, 138, 104784.	2.1	65
579	APOE4 moderates effects of cortical iron on synchronized default mode network activity in cognitively healthy oldâ€aged adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12002.	1.2	23
580	Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How. Neurobiology of Disease, 2020, 139, 104811.	2.1	44
581	Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 19.	3.0	29
582	Therapeutic IDOL Reduction Ameliorates Amyloidosis and Improves Cognitive Function in APP/PS1 Mice. Molecular and Cellular Biology, 2020, 40, .	1.1	8

#	Article	IF	Citations
583	Apolipoprotein E Interferes with IAPP Aggregation and Protects Pericytes from IAPP-Induced Toxicity. Biomolecules, 2020, 10, 134.	1.8	14
584	Dietary Lactoferrin Supplementation Prevents Memory Impairment and Reduces Amyloid-Î² Generation in J20 Mice. Journal of Alzheimer's Disease, 2020, 74, 245-259.	1.2	24
585	Reduced Influence of apoE on AÎ²43 Aggregation and Reduced Vascular AÎ²43 Toxicity as Compared with AÎ²40 and AÎ²42. Molecular Neurobiology, 2020, 57, 2131-2141.	1.9	6
586	Therapeutic approaches targeting Apolipoprotein E function in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2020, 15, 8.	4.4	89
587	Amyloid Î²-protein and beyond: the path forward in Alzheimerâ€™s disease. Current Opinion in Neurobiology, 2020, 61, 116-124.	2.0	87
588	Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach. Alzheimer's and Dementia, 2020, 16, 862-872.	0.4	17
589	A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery. European Journal of Medicinal Chemistry, 2020, 195, 112275.	2.6	72
590	Apolipoprotein E Facilitates Amyloid-Î² Oligomer-Induced Tau Phosphorylation. Journal of Alzheimer's Disease, 2020, 74, 521-534.	1.2	9
591	The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimerâ€™s Disease. Frontiers in Immunology, 2020, 11, 754.	2.2	100
592	Utility of spontaneous animal models of Alzheimerâ€™s disease in preclinical efficacy studies. Cell and Tissue Research, 2020, 380, 273-286.	1.5	10
593	Amyloidâ€Î² oligomers in cellular models of Alzheimerâ€™s disease. Journal of Neurochemistry, 2020, 155, 348-369.	2.1	50
595	Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules. Brain Research Bulletin, 2020, 160, 121-140.	1.4	72
596	The Apolipoprotein E Îµ4 Allele-Dependent Relationship Between Serum Lipid Levels and Cognitive Function: A Population-Based Cross-sectional Study. Frontiers in Aging Neuroscience, 2020, 12, 44.	1.7	10
597	The Sleep Side of Aging and Alzheimerâ€™s Disease. Sleep Medicine, 2021, 77, 209-225.	0.8	29
598	Î²â€Amyloid may accumulate in the human brain after focal bacterial infection: An ¹⁸Fâ€flutemetamol positron emission tomography study. European Journal of Neurology, 2021, 28, 877-883.	1.7	6
599	A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy. Medicinal Research Reviews, 2021, 41, 2689-2745.	5.0	26
600	Design and Validation of Liposomal ApoE2 Gene Delivery System to Evade Bloodâ€“Brain Barrier for Effective Treatment of Alzheimerâ€™s Disease. Molecular Pharmaceutics, 2021, 18, 714-725.	2.3	69
601	Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis. Neuron, 2021, 109, 205-221.	3.8	139

#	Article	IF	Citations
602	APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurology, The, 2021, 20, 68-80.	4.9	399
603	Multifunctional Nanostructure RAPâ€RL Rescues Alzheimer's Cognitive Deficits through Remodeling the Neurovascular Unit. Advanced Science, 2021, 8, 2001918.	5.6	4
604	Blood lipid markers are associated with hippocampal viscoelastic properties and memory in humans. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1417-1427.	2.4	8
605	APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia. Alzheimer's and Dementia, 2021, 17, 61-69.	0.4	39
606	A peptide fraction of Olive Flounder (Paralichthys olivaceus) Skin Hydrolysate Inhibits Amyloid-Î² Generation in SH-SY5Y Cells via Suppression of BACE1 Expression. International Journal of Peptide Research and Therapeutics, 2021, 27, 627-639.	0.9	1
607	Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1696.	3.3	3
608	Alzheimerâ€™s disease: a tale of two diseases?. Neural Regeneration Research, 2021, 16, 1958.	1.6	15
609	Sex and sex hormone differences in hippocampal neurogenesis and their relevance to Alzheimerâ€™s disease. , 2021, , 23-77.		3
610	Gene therapy-mediated enhancement of protective protein expression for the treatment of Alzheimerâ€™s disease. Brain Research, 2021, 1753, 147264.	1.1	5
611	Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model. Annals of Neurology, 2021, 89, 952-966.	2.8	36
612	Mitochondriaâ€associated endoplasmic reticulum membranes: At the crossroad between familiar and sporadic Alzheimer's disease. Synapse, 2021, 75, e22196.	0.6	8
613	APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Science Translational Medicine, 2021, 13, .	5.8	76
614	Physiological and Pathological Ageing of Astrocytes in the Human Brain. Neurochemical Research, 2021, 46, 2662-2675.	1.6	30
615	The Human ApoE4 Variant Reduces Functional Recovery and Neuronal Sprouting After Incomplete Spinal Cord Injury in Male Mice. Frontiers in Cellular Neuroscience, 2021, 15, 626192.	1.8	7
616	Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia. NeuroMolecular Medicine, 2021, 23, 1-24.	1.8	9
617	Blood NCAPH2 Methylation Is Associated With Hippocampal Volume in Subjective Cognitive Decline With Apolipoprotein E Îµ4 Non-carriers. Frontiers in Aging Neuroscience, 2021, 13, 632382.	1.7	4
618	APOE and Alzheimerâ€™s Disease: From Lipid Transport to Physiopathology and Therapeutics. Frontiers in Neuroscience, 2021, 15, 630502.	1.4	129
619	Pericytes and the Neurovascular Unit: The Critical Nexus of Alzheimer Disease Pathogenesis?. Exploratory Research and Hypothesis in Medicine, 2021, 000, 000-000.	0.1	0

#	Article	IF	Citations
620	A cross-sectional examination of a family history of Alzheimer's disease and ApoE epsilon 4 on physical fitness, molecular biomarkers, and neurocognitive performance. Physiology and Behavior, 2021, 230, 113268.	1.0	6
621	Pharmacological ablation of astrocytes reduces Aî² degradation and synaptic connectivity in an ex vivo model of Alzheimerâ€™s disease. Journal of Neuroinflammation, 2021, 18, 73.	3.1	25
622	The Protective A673T Mutation of Amyloid Precursor Protein (APP) in Alzheimerâ€™s Disease. Molecular Neurobiology, 2021, 58, 4038-4050.	1.9	16
624	Amyloid Î² Clearance Is Disrupted by Depletion of Low-Density Lipoprotein Receptor-Related Protein 4 (LRP4) in Astrocytes. Journal of Neuroscience, 2021, 41, 3749-3751.	1.7	3
625	Alternative Targets to Fight Alzheimerâ€™s Disease: Focus on Astrocytes. Biomolecules, 2021, 11, 600.	1.8	16
626	ApoE4 inhibition of VMAT2 in the locus coeruleus exacerbates Tau pathology in Alzheimerâ€™s disease. Acta Neuropathologica, 2021, 142, 139-158.	3.9	21
627	Analysis of whole genome sequenced cases and controls shows that the association of variants in TOMM40, BCAM, NECTIN2 and APOC1 with late onset Alzheimerâ€™s disease is driven by linkage disequilibrium with APOE Îµ2/Îµ3/Îµ4 alleles. Journal of Neurogenetics, 2021, 35, 59-66.	0.6	3
628	Alzheimerâ€™s Disease: New Concepts on the Role of Autoimmunity and NLRP3 Inflammasome in the Pathogenesis of the Disease. Current Neuropharmacology, 2021, 19, 498-512.	1.4	16
629	MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimerâ€™s disease. BMC Neuroscience, 2021, 22, 39.	0.8	25
630	Molecular subtyping of Alzheimerâ€™s disease with consensus non-negative matrix factorization. PLoS ONE, 2021, 16, e0250278.	1.1	16
631	Elevating the Levels of Calcium Ions Exacerbate Alzheimerâ€™s Disease via Inducing the Production and Aggregation of Î²-Amyloid Protein and Phosphorylated Tau. International Journal of Molecular Sciences, 2021, 22, 5900.	1.8	38
632	Effects of amyloid pathology and the APOE Îµ4 allele on the association between cerebrospinal fluid Aî²38 and Aî²40 and brain morphology in cognitively normal 70-years-olds. Neurobiology of Aging, 2021, 101, 1-12.	1.5	7
633	Biomarkers and Their Implications in Alzheimerâ€™s Disease: A Literature Review. Exploratory Research and Hypothesis in Medicine, 2021, 000, 000-000.	0.1	5
634	Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy. Frontiers in Aging Neuroscience, 2021, 13, 658605.	1.7	11
635	Upregulation of APP endocytosis by neuronal aging drives amyloid-dependent synapse loss. Journal of Cell Science, 2021, 134, .	1.2	29
636	Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron, 2021, 109, 1657-1674.e7.	3.8	151
637	The role of amyloid oligomers in neurodegenerative pathologies. International Journal of Biological Macromolecules, 2021, 181, 582-604.	3.6	38
638	Association of APOE Îµ4 genotype and lifestyle with cognitive function among Chinese adults aged 80 years and older: A cross-sectional study. PLoS Medicine, 2021, 18, e1003597.	3.9	46

#	Article	IF	Citations
639	Cholesterol and Alzheimerâ€™s Disease; From Risk Genes to Pathological Effects. Frontiers in Aging Neuroscience, 2021, 13, 690372.	1.7	110
640	The Role of ApoE Expression and Variability of Its Glycosylation in Human Reproductive Health in the Light of Current Information. International Journal of Molecular Sciences, 2021, 22, 7197.	1.8	12
641	GWAS-Top Polymorphisms Associated With Late-Onset Alzheimer Disease in Brazil: Pointing Out Possible New Culprits Among Non-Coding RNAs. Frontiers in Molecular Biosciences, 2021, 8, 632314.	1.6	3
643	Arterial stiffening acts synergistically with APOE genotype and AD biomarker status to influence memory in older adults without dementia. Alzheimer's Research and Therapy, 2021, 13, 121.	3.0	8
644	Biomarkers for the Clinical Diagnosis of Alzheimerâ€™s Disease: Metabolomics Analysis of Brain Tissue and Blood. Frontiers in Pharmacology, 2021, 12, 700587.	1.6	11
645	Segmented Linear Mixed Model Analysis Reveals Association of the APOE É›4 Allele with Faster Rate of Alzheimerâ€™s Disease Dementia Progression. Journal of Alzheimer's Disease, 2021, 82, 921-937.	1.2	13
646	Treatments for Alzheimer's disease emerge. Science, 2021, 373, 624-626.	6.0	75
647	Planar cell polarity signaling components are a direct target of Î²-amyloidâ€“associated degeneration of glutamatergic synapses. Science Advances, 2021, 7, .	4.7	14
648	Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases. Current Neurovascular Research, 2021, 18, 150-161.	0.4	5
649	Aggregate Trends of Apolipoprotein E on Cognition in Transgenic Alzheimerâ€™s Disease Mice. Journal of Alzheimer's Disease, 2021, 83, 435-450.	1.2	4
650	Looking at Alzheimerâ€™s Disease Pathogenesis from the Nuclear Side. Biomolecules, 2021, 11, 1261.	1.8	3
651	From Menopause to Neurodegenerationâ€”Molecular Basis and Potential Therapy. International Journal of Molecular Sciences, 2021, 22, 8654.	1.8	24
652	The Amyloid-Î² Pathway in Alzheimerâ€™s Disease. Molecular Psychiatry, 2021, 26, 5481-5503.	4.1	478
653	Research Progress on Mechanism of Neuroprotective Roles of Apelin-13 in Prevention and Treatment of Alzheimerâ€™s Disease. Neurochemical Research, 2022, 47, 205-217.	1.6	13
654	A Review of Oxidative Stress Products and Related Genes in Early Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 83, 977-1001.	1.2	34
655	Astrocytes in Neurodegenerative Diseases: A Perspective from Tauopathy and Î±-Synucleinopathy. Life, 2021, 11, 938.	1.1	13
656	Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid-Î². Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158980.	1.2	14
657	A Review of APOE Genotype-Dependent Autophagic Flux Regulation in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 84, 535-555.	1.2	7

#	Article	IF	Citations
658	Absence of Apolipoprotein E is associated with exacerbation of prion pathology and promotes microglial neurodegenerative phenotype. Acta Neuropathologica Communications, 2021, 9, 157.	2.4	6
659	Smaller hippocampal volume in APOE Îµ4 carriers independent of amyloid-Î² (AÎ²) burden. Psychiatry Research - Neuroimaging, 2021, 317, 111381.	0.9	2
660	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. Neurobiology of Aging, 2021, 108, 90-98.	1.5	11
661	Pathological mechanisms and therapeutic strategies for Alzheimerâ€™s disease. Neural Regeneration Research, 2022, 17, 543.	1.6	146
663	Neuropathology of HIV-1 Disease. , 2017, , 143-208.		2
664	Altered lipid metabolic homeostasis in the pathogenesis of Alzheimerâ€™s disease. , 2020, , 469-504.		5
665	Sex-related Differences in Tau Positron Emission Tomography (PET) and the Effects of Hormone Therapy (HT). Alzheimer Disease and Associated Disorders, 2021, 35, 164-168.	0.6	30
670	APOE4-mediated amyloid-Î² pathology depends on its neuronal receptor LRP1. Journal of Clinical Investigation, 2019, 129, 1272-1277.	3.9	96
671	In vivo kinetic approach reveals slow SOD1 turnover in the CNS. Journal of Clinical Investigation, 2015, 125, 2772-2780.	3.9	46
672	Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. Journal of Clinical Investigation, 2018, 128, 2144-2155.	3.9	105
673	Blocking the apoE/AÃŸ interaction ameliorates AÃŸ-related pathology in APOE Â¿2 and Â¿4 targeted replacement Alzheimer model mice. Acta Neuropathologica Communications, 2014, 2, 75.	2.4	36
674	Inconsistencies and controversies surrounding the Amyloid Hypothesis of AlzheimerÂ¿s disease. Acta Neuropathologica Communications, 2014, 2, 135.	2.4	186
675	In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS. PLoS ONE, 2012, 7, e38013.	1.1	43
676	Disruption of Arterial Perivascular Drainage of Amyloid-Î² from the Brains of Mice Expressing the Human APOE Îµ4 Allele. PLoS ONE, 2012, 7, e41636.	1.1	138
677	The Liver X Receptor Agonist GW3965 Improves Recovery from Mild Repetitive Traumatic Brain Injury in Mice Partly through Apolipoprotein E. PLoS ONE, 2013, 8, e53529.	1.1	43
678	Prevalence of Alzheimerâ€™s Pathologic Endophenotypes in Asymptomatic and Mildly Impaired First-Degree Relatives. PLoS ONE, 2013, 8, e60747.	1.1	18
679	Effects of NR1H3 Genetic Variation on the Expression of Liver X Receptor Î± and the Progression of Alzheimer's Disease. PLoS ONE, 2013, 8, e80700.	1.1	16
680	Overexpression of the IGF-II/M6P Receptor in Mouse Fibroblast Cell Lines Differentially Alters Expression Profiles of Genes Involved in Alzheimerâ€™s Disease-Related Pathology. PLoS ONE, 2014, 9, e98057.	1.1	5

#	Article	IF	Citations
681	Intracellular Clusterin Interacts with Brain Isoforms of the Bridging Integrator 1 and with the Microtubule-Associated Protein Tau in Alzheimer's Disease. PLoS ONE, 2014, 9, e103187.	1.1	71
682	Demographic and Lifestyle Characteristics, but Not Apolipoprotein E Genotype, Are Associated with Intelligence among Young Chinese College Students. PLoS ONE, 2015, 10, e0143157.	1.1	5
683	Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice. PLoS ONE, 2017, 12, e0172161.	1.1	16
684	APOE Îµ4-TOMM40 â€˜523 haplotypes and the risk of Alzheimerâ€™s disease in older Caucasian and African Americans. PLoS ONE, 2017, 12, e0180356.	1.1	39
685	The protective mutation A673T in amyloid precursor protein gene decreases AÎ² peptides production for 14 forms of Familial Alzheimerâ€™s Disease in SH-SY5Y cells. PLoS ONE, 2020, 15, e0237122.	1.1	11
686	Genetic Pathways of Neuroregeneration in a Novel Mild Traumatic Brain Injury Model in Adult Zebrafish. ENeuro, 2018, 5, ENEURO.0208-17.2017.	0.9	27
687	Updated meta-analysis of the role ofAPOEÎµ2/Îµ3/Îµ4 alleles in frontotemporal lobar degeneration. Oncotarget, 2017, 8, 43721-43732.	0.8	9
688	A plasma proteolysis pathway comprising blood coagulation proteases. Oncotarget, 0, 7, 40919-40938.	0.8	22
689	Impaired macrophage autophagy induces systemic insulin resistance in obesity. Oncotarget, 2016, 7, 35577-35591.	0.8	72
690	TÃ¼rk PopÃ¼lasyonunda APOE Polimorfizmleri ve Alzheimer HastalÄ±ÄŸÄ± ArasÄ±ndaki Ä°liÅŸki. OsmangazÄ° Journal of Medicine, 0, 00, .	0.1	1
691	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. Current Pharmaceutical Design, 2020, 26, 1286-1299.	0.9	12
692	A Systematic Review of Current Progresses in the Nucleic Acid-Based Therapies for Neurodegeneration with Implications for Alzheimerâ€™s Disease. Mini-Reviews in Medicinal Chemistry, 2020, 20, 1499-1517.	1.1	14
693	Molecular Basis of Familial and Sporadic Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 952-963.	0.7	241
694	Therapeutic Noninvasive Brain Stimulation in Alzheimerâ€™s Disease. Current Alzheimer Research, 2017, 14, 362-376.	0.7	47
695	Integrated Genomic Analysis Revealed Associated Genes for Alzheimerâ€™s Disease in APOE4 Non-Carriers. Current Alzheimer Research, 2019, 16, 753-763.	0.7	9
696	Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease. Current Alzheimer Research, 2020, 17, 344-354.	0.7	18
697	The Links between Cardiovascular Diseases and Alzheimer's Disease. Current Neuropharmacology, 2020, 19, 152-169.	1.4	23
698	Opposing Roles of apolipoprotein E in aging and neurodegeneration. Life Science Alliance, 2019, 2, e201900325.	1.3	20

#	Article	IF	Citations
699	An Exploration of the Oryza sativa L. Cyanidin-3-glucoside on the Cognitive Function in Older Adults with Subjective Memory Impairment. Psychiatry Investigation, 2019, 16, 759-765.	0.7	8
700	Accumulation of Cerebrospinal Fluid Glycerophospholipids and Sphingolipids in Cognitively Healthy Participants With Alzheimerâ€™s Biomarkers Precedes Lipolysis in the Dementia Stage. Frontiers in Neuroscience, 2020, 14, 611393.	1.4	11
701	Physiological and Pathological Functions of Beta-Amyloid in the Brain and Alzheimer'S Disease. Chinese Journal of Physiology, 2020, 63, 95-100.	0.4	11
702	Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels. ELife, 2017, 6, .	2.8	83
703	Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimerâ€™s disease. ELife, 2018, 7, .	2.8	62
704	Fibrillar AÎ² triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. ELife, 2020, 9, .	2.8	80
705	The development and physiological and pathophysiological functions of resident macrophages and glial cells. Advances in Immunology, 2021, 151, 1-47.	1.1	2
706	Decreased Global EEG Synchronization in Amyloid Positive Mild Cognitive Impairment and Alzheimerâ€™s Disease Patientsâ€”Relationship to APOE Îµ4. Brain Sciences, 2021, 11, 1359.	1.1	8
707	Microgliaâ€specific <scp>ApoE</scp> knockâ€out does not alter Alzheimer's disease plaque pathogenesis or gene expression. Glia, 2022, 70, 287-302.	2.5	20
708	Apolipoprotein E and Alzheimer's disease. Acta Pharmaceutica Sinica B, 2022, 12, 496-510.	5.7	30
709	Microglial transcription profiles in mouse and human are driven by APOE4 and sex. IScience, 2021, 24, 103238.	1.9	9
710	The LXR/RXR Approaches in Alzheimerâ€™s Disease: Is the Blood-Bra in Barrier the Forgotten Partner?. , 2013, 03, .		1
711	GÃ©nÃ©tique des formes autosomiques dominantes de maladie dâ€™Alzheimer. , 2013, , 157-174.		0
712	Genetic Models of Alzheimerâ€™s Disease: The Influence of Apolipoprotein E allele Isoforms on Behaviour in Laboratory Animals. , 2016, , 199-228.		0
713	Genetic risk factor APOEÎµ4 associates with plasma amyloid beta in amnestic mild cognitive impairment and alzheimerâ€™s disease. Medical Journal of Indonesia, 2016, 25, 44-50.	0.2	0
715	Solving the Puzzle of Neurodegeneration. , 2018, , 1-22.		2
717	Do Cardiometabolic Risk Factors Influence Amyloid, Tau, and Neuronal Function in APOE4 Carriers and Non-Carriers in Alzheimerâ€™s Disease Trajectory?. Journal of Alzheimer's Disease, 2018, , 1-13.	1.2	0
721	AsociaciÃ³n de obesidad y dislipidemia con el riesgo de progresiÃ³n a deterioro cognitivo leve y demencia: revisiÃ³n sistemÃ¡tica. Repertorio De Medicina Y Cirugia, 0, , 20.	0.0	1

#	Article	IF	Citations
722	Advances in Modeling Alzheimer's Disease In Vitro. Advanced NanoBiomed Research, 2021, 1, 2100097.	1.7	10
723	Expression and proteolytic processing of the amyloid precursor protein is unaffected by the expression of the three human apolipoprotein E alleles in the brains of mice. Neurobiology of Aging, 2022, 110, 73-76.	1.5	3
725	Genomics of Alzheimerâ€™s disease. , 2020, , 3-18.		0
726	Molecular Modelling Based Design and Synthesis of Donepezil Like Derivatives As Acetylcholinesterase Inhibitors. SSRN Electronic Journal, 0, , .	0.4	1
727	Genetic predisposition to Alzheimer's disease. Profese Online, 2020, 13, 10-16.	0.1	0
731	Analysis of apolipoprotein E genetic variation in patients with Alzheimer disease referred to Imam Reza Clinic, Rasht, Iran, in 2015. Iranian Journal of Neurology, 2017, 16, 173-177.	0.5	4
732	Axonal plasma membrane-mediated toxicity of cholesterol in Alzheimer's disease: A microsecond molecular dynamics study. Biophysical Chemistry, 2022, 281, 106718.	1.5	7
733	Cholesterol Dysmetabolism in Alzheimerâ€™s Disease: A Starring Role for Astrocytes?. Antioxidants, 2021, 10, 1890.	2.2	20
734	The potential roles of excitatory-inhibitory imbalances and the repressor element-1 silencing transcription factor in aging and aging-associated diseases. Molecular and Cellular Neurosciences, 2021, 117, 103683.	1.0	12
735	Presenilin Is Essential for ApoE Secretion, a Novel Role of Presenilin Involved in Alzheimer's Disease Pathogenesis. Journal of Neuroscience, 2022, 42, 1574-1586.	1.7	8
736	APOE4 confers transcriptomic and functional alterations to primary mouse microglia. Neurobiology of Disease, 2022, 164, 105615.	2.1	22
737	Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials. Neurotherapeutics, 2022, 19, 8-25.	2.1	26
738	Modulation of retinoid-X-receptors differentially regulates expression of apolipoprotein genes apoc1 and apoeb by zebrafish microglia. Biology Open, 2022, 11, .	0.6	6
739	Mechanistic Link between Vitamin B12 and Alzheimerâ€™s Disease. Biomolecules, 2022, 12, 129.	1.8	26
740	Isoform-dependent lysosomal degradation and internalization of apolipoprotein E requires autophagy proteins. Journal of Cell Science, 2022, 135, .	1.2	16
741	The Cause of Alzheimerâ€™s Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress. , 2022, 13, 37.		22
743	Selective reduction of astrocyte apoE3 and apoE4 strongly reduces AÎ² accumulation and plaque-related pathology in a mouse model of amyloidosis. Molecular Neurodegeneration, 2022, 17, 13.	4.4	44
744	Association of APOE Îµ4 with cerebral gray matter volumes in non-demented older adults: The MEMENTO cohort study. NeuroImage, 2022, 250, 118966.	2.1	11

#	Article	IF	Citations
745	Factors Influencing Alzheimerâ€™s Disease Risk: Whether and How They are Related to the APOE Genotype. Neuroscience Bulletin, 2022, 38, 809-819.	1.5	5
746	The Emergence of Model Systems to Investigate the Link Between Traumatic Brain Injury and Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 813544.	1.7	5
748	Are apolipoprotein E fragments a promising new therapeutic target for Alzheimerâ€™s disease?. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232210816.	1.1	8
749	APOE mediated neuroinflammation and neurodegeneration in Alzheimerâ€™s disease. Seminars in Immunology, 2022, 59, 101594.	2.7	58
750	N-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases. Antioxidants, 2022, 11, 416.	2.2	10
751	Effects of APOE4 allelic dosage on lipidomic signatures in the entorhinal cortex of aged mice. Translational Psychiatry, 2022, 12, 129.	2.4	21
752	Endogenous Human Proteins Interfering with Amyloid Formation. Biomolecules, 2022, 12, 446.	1.8	9
753	Lipoprotein-Inspired Nanoscavenger for the Three-Pronged Modulation of Microglia-Derived Neuroinflammation in Alzheimerâ€™s Disease Therapy. Nano Letters, 2022, 22, 2450-2460.	4.5	22
754	Normal cerebrospinal fluid concentrations of PDGFRÎ² in patients with cerebral amyloid angiopathy and Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 1788-1796.	0.4	6
755	Nanocomposites Facilitate the Removal of AÎ² Fibrils for Neuroprotection. Chemical Research in Chinese Universities, 0, , 1.	1.3	1
756	The Relationship Between Sleep Disturbance and Apolipoprotein E Îµ4 in Adults With Mild Cognitive Impairment and Alzheimerâ€™s Disease Dementia: An Integrative Review. Biological Research for Nursing, 2022, 24, 327-337.	1.0	2
757	No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. PLoS ONE, 2022, 17, e0266615.	1.1	5
758	Stereotaxic-assisted gene therapy in Alzheimerâ€™s and Parkinsonâ€™s diseases: therapeutic potentials and clinical frontiers. Expert Review of Neurotherapeutics, 2022, 22, 319-335.	1.4	1
771	Apolipoprotein E4 Effects a Distinct Transcriptomic Profile and Dendritic Arbor Characteristics in Hippocampal Neurons Cultured in vitro. Frontiers in Aging Neuroscience, 2022, 14, 845291.	1.7	2
772	The role of ATP-binding cassette subfamily A in the etiology of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2022, 17, 31.	4.4	16
773	Single-Cell Analysis of the Peripheral Immune Landscape in Alzheimer's Disease Reveals a Distinct Adaptive Immune Signature. SSRN Electronic Journal, 0, , .	0.4	0
774	Impact of APOE Îµ4 Carrier Status on Associations Between Subthreshold, Positive Amyloid-Î² Deposition, Brain Function, and Cognitive Performance in Cognitively Normal Older Adults: A Prospective Study. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
775	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	4.5	31

#	Article	IF	Citations
778	Targeting the alternative oxidase (AOX) for human health and food security, a pharmaceutical and agrochemical target or a rescue mechanism?. Biochemical Journal, 2022, 479, 1337-1359.	1.7	6
779	DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease. Current Medicinal Chemistry, 2023, 30, 669-688.	1.2	8
780	Brain Amyloid- ÃŸ Accumulation in AD Mouse Models Modified by Their Altered Gene Expression in the Presence of Human apoE Isoforms Through Aging Process. SSRN Electronic Journal, 0, , .	0.4	0
781	Vascular Dysfunction Is Central to Alzheimerâ€™s Disease Pathogenesis in APOE e4 Carriers. International Journal of Molecular Sciences, 2022, 23, 7106.	1.8	5
782	Association of APOE Genotypes and Chronic Traumatic Encephalopathy. JAMA Neurology, 2022, 79, 787.	4.5	27
783	An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-Îµ4 in female patients with Alzheimerâ€™s disease. Nature Aging, 2022, 2, 616-634.	5.3	11
784	Crossing borders in Alzheimerâ€™s disease: A T cellâ€™s perspective. Advanced Drug Delivery Reviews, 2022, 188, 114398.	6.6	13
785	If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?. PLoS Biology, 2022, 20, e3001694.	2.6	67
786	Plasma highâ€density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume. Journal of Neurochemistry, 2022, 163, 53-67.	2.1	6
787	Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimerâ€™s disease. Journal of Neuroinflammation, 2022, 19, .	3.1	80
788	Associations Between Sub-Threshold Amyloid-Î² Deposition, Cortical Volume, and Cognitive Function Modulated by APOE É›4 Carrier Status in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2022, , 1-14.	1.2	0
789	Peripheral apoE4 enhances Alzheimerâ€™s pathology and impairs cognition by compromising cerebrovascular function. Nature Neuroscience, 2022, 25, 1020-1033.	7.1	57
790	Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice. MAbs, 2022, 14, .	2.6	5
791	Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS). EBioMedicine, 2022, 83, 104241.	2.7	8
792	Interplay between aging and other factors of the pathogenesis of age-related macular degeneration. Ageing Research Reviews, 2022, 81, 101735.	5.0	16
793	Basics of amyloid Î²-protein in Alzheimerâ€™s disease. , 2022, , 73-89.		0
797	A review of brain imaging biomarker genomics in Alzheimerâ€™s disease: implementation and perspectives. Translational Neurodegeneration, 2022, 11, .	3.6	9
798	Building in vitro models of the brain to understand the role ofAPOEin Alzheimerâ€™s disease. Life Science Alliance, 2022, 5, e202201542.	1.3	2

#	Article	IF	Citations
800	APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimerâ€™s disease pathology and brain diseases. Molecular Neurodegeneration, 2022, 17, .	4.4	62
801	Neurocognitive trajectory and proteomic signature of inherited risk for Alzheimerâ€™s disease. PLoS Genetics, 2022, 18, e1010294.	1.5	3
802	Pathophysiology of Alzheimerâ€™s Disease. Psychiatric Clinics of North America, 2022, , .	0.7	9
803	Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders. Nature Reviews Neuroscience, 2023, 24, 23-39.	4.9	107
804	APOE Îµ4-dependent effects on the early amyloid pathology in induced neuronsÂof patients with Alzheimerâ€™s disease. Translational Neurodegeneration, 2022, 11, .	3.6	5
805	Amyloid Î², Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 12092.	1.8	7
806	Ovariectomy-induced hormone deprivation aggravates AÎ²1-42 deposition in the basolateral amygdala and cholinergic fiber loss in the cortex but not cognitive behavioral symptoms in a triple transgenic mouse model of Alzheimerâ€™s disease. Frontiers in Endocrinology, 0, 13, .	1.5	3
807	Patients with Alzheimerâ€™s disease have an increased removal rate of soluble beta-amyloid-42. PLoS ONE, 2022, 17, e0276933.	1.1	7
808	An emerging role of astrocytes in aging/neuroinflammation and gut-brain axis with consequences on sleep and sleep disorders. Ageing Research Reviews, 2023, 83, 101775.	5.0	14
809	Pharmacological Treatment of Alzheimerâ€™s Disease. Advances in Biological Psychiatry, 2012, , 122-167.	0.2	3
810	Hypothesis on ontogenesis and pathophysiology of Alzheimerâ€™s disease. Einstein (Sao Paulo, Brazil), 2022, 20, .	0.3	4
811	APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature, 2022, 611, 769-779.	13.7	144
812	Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study. Brain, 2023, 146, 337-348.	3.7	22
814	Exercise modulates APOE expression in brain cortex of female APOE3 and APOE4 targeted replacement mice. Neuropeptides, 2023, 97, 102307.	0.9	4
815	Infectious origin of Alzheimerâ€™s disease: Amyloid beta as a component of brain antimicrobial immunity. PLoS Pathogens, 2022, 18, e1010929.	2.1	22
816	Nerve injury-induced upregulation of apolipoprotein E in dorsal root ganglion participates in neuropathic pain in male mice. Neuropharmacology, 2023, 224, 109372.	2.0	4
817	Effect of APOE Îµ4 genotype on amyloidâ€Î², glucose metabolism, and gray matter volume in cognitively normal individuals and amnestic mild cognitive impairment. European Journal of Neurology, 2023, 30, 587-596.	1.7	3
818	Serum unsaturated phosphatidylcholines predict longitudinal basal forebrain degeneration in Alzheimerâ€™s disease. Brain Communications, 2022, 4, .	1.5	3

#	Article	IF	Citations
819	Differences in resting state functional connectivity underlie visuomotor performance declines in older adults with a genetic risk (APOE Îµ4) for Alzheimerâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	0
820	Accumulation of amyloid-Î² in the brain of mouse models of Alzheimer's disease is modified by altered gene expression in the presence of human apoE isoforms during aging. Neurobiology of Aging, 2023, 123, 63-74.	1.5	2
821	Predictive link between systemic metabolism and cytokine signatures in the brain of apolipoprotein E Îµ4 mice. Neurobiology of Aging, 2022, , .	1.5	6
822	Apolipoprotein <scp>E4</scp> inhibits Î³â€secretase activity via binding to the Î³â€secretase complex. Journal of Neurochemistry, 2023, 164, 858-874.	2.1	2
824	APOE effects on regional tau in preclinical Alzheimerâ€™s disease. Molecular Neurodegeneration, 2023, 18, .	4.4	10
825	LilrB3 is a putative cell surface receptor of APOE4. Cell Research, 2023, 33, 116-130.	5.7	10
826	Neuroprotective properties of <scp>DPP</scp>â€4i: A therapeutic target for dementia prevention in elderly diabetic patients?. Journal of Diabetes Investigation, 2023, 14, 525-527.	1.1	0
827	Gut microbes modulate neurodegeneration. Science, 2023, 379, 142-143.	6.0	1
828	Molecular biomarkers and cognitive impairment in multiple sclerosis: State of the field, limitations, and future direction â€“ A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2023, 146, 105035.	2.9	6
831	A Function of Amyloid-Î² in Mediating Activity-Dependent Axon/Synapse Competition May Unify Its Roles in Brain Physiology and Pathology. Journal of Alzheimer's Disease, 2023, , 1-29.	1.2	2
832	How does apolipoprotein E genotype influence the relationship between physical activity and Alzheimerâ€™s disease risk? A novel integrative model. Alzheimer's Research and Therapy, 2023, 15, .	3.0	6
833	Role of Lipids in Regulation of Neuroglial Interactions. Biochemistry (Moscow), 2023, 88, 337-352.	0.7	0
834	Peripheral apolipoprotein E proteins and their binding to LRP1 antagonize Alzheimerâ€™s disease pathogenesis in the brain during peripheral chronic inflammation. Neurobiology of Aging, 2023, 127, 54-69.	1.5	4
835	Relationship of Apolipoprotein E with Alzheimerâ€™s Disease and Other Neurological Disorders: An Updated Review. Neuroscience, 2023, 514, 123-140.	1.1	3
836	Mitochondria Profoundly Influence Apolipoprotein E Biology. Journal of Alzheimer's Disease, 2023, 92, 591-604.	1.2	6
837	The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells. Biomolecules, 2023, 13, 313.	1.8	8
839	Imaging Amyloidâ€Î² Membrane Interactions: Ionâ€Channel Pores and Lipidâ€Bilayer Permeability in Alzheimer's Disease. Angewandte Chemie, 2023, 135, .	1.6	0
840	Imaging Amyloidâ€Î² Membrane Interactions: Ionâ€Channel Pores and Lipidâ€Bilayer Permeability in Alzheimer's Disease. Angewandte Chemie - International Edition, 2023, 62, .	7.2	9

#	Article	IF	Citations
841	N-acetylneuraminic acid links immune exhaustion and accelerated memory deficit in diet-induced obese Alzheimerâ€™s disease mouse model. Nature Communications, 2023, 14, .	5.8	7
842	Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy. Molecular Neurodegeneration, 2023, 18, .	4.4	7
843	MMP2 rs243866 and rs2285053 Polymorphisms and Alzheimerâ€™s Disease Risk in Slovak Caucasian Population. Life, 2023, 13, 882.	1.1	0
844	Brain Amyloid in Sporadic Young Onset Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2023, 7, 263-270.	1.2	1
845	Multifaceted Roles of Aquaporins in the Pathogenesis of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2023, 24, 6528.	1.8	5
846	Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimerâ€™s disease. Trends in Neurosciences, 2023, 46, 426-444.	4.2	11
847	APOE Îµ4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly. Alzheimer's Research and Therapy, 2023, 15, .	3.0	5
848	Mediation of Reduced Hippocampal Volume by Cerebral Amyloid Angiopathy in Pathologically Confirmed Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2023, , 1-13.	1.2	1
849	Vascular Risk Predicts Plasma Amyloid Î² 42/40 Through Cerebral Amyloid Burden in Apolipoprotein E Îµ4 Carriers. Stroke, 0, , .	1.0	0
850	Amyloid-beta aggregation implicates multiple pathways in Alzheimerâ€™s disease: Understanding the mechanisms. Frontiers in Neuroscience, 0, 17, .	1.4	10
851	Effects of intermittent fasting on cognitive health and Alzheimerâ€™s disease. Nutrition Reviews, 2023, 81, 1225-1233.	2.6	11
852	A haptoglobin (HP) structural variant alters the effect of APOE alleles on Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 4886-4895.	0.4	1
853	Recent Development in the Understanding of Molecular and Cellular Mechanisms Underlying the Etiopathogenesis of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2023, 24, 7258.	1.8	7
854	Apolipoprotein E O-glycosylation is associated with amyloid plaques and APOE genotype. Analytical Biochemistry, 2023, 672, 115156.	1.1	1
859	Roles of ApoE4 on the Pathogenesis in Alzheimerâ€™s Disease and the Potential Therapeutic Approaches. Cellular and Molecular Neurobiology, 2023, 43, 3115-3136.	1.7	7
862	Recent Advances in Photoelectrochemical Sensing of Alzheimerâ€™s Biomarkers. Biochip Journal, 2023, 17, 218-229.	2.5	0
867	Clinical relevance of animal models in aging-related dementia research. Nature Aging, 2023, 3, 481-493.	5.3	5
869	Fatigue in Alzheimerâ€™s disease: biological basis and clinical managementâ€”a narrative review. Aging Clinical and Experimental Research, 2023, 35, 1981-1989.	1.4	2

#	Article	IF	Citations
872	ApoE Mimetic Peptides as Therapy for Traumatic Brain Injury. Neurotherapeutics, 2023, 20, 1496-1507.	2.1	1
884	Emerging diagnostics and therapeutics for Alzheimer disease. Nature Medicine, 2023, 29, 2187-2199.	15.2	20
891	Stem Cells Vs Exosomes: Promising Therapeutic Approach and Biomarkers Agent against Neurodegenerative Disorders. , 2023, , 169-191.		0
906	Designing Nanodiscs as Versatile Platforms for On-Demand Therapy. Nanoscale, 0, , .	2.8	0